Home / Recent DM Research Publications

Recent DM Research Publications

Cells of Matter-In Vitro Models for Myotonic Dystrophy.
Matloka M, Klein AF, Rau F, Furling D.
Front Neurol. 2018 May 23;9:361. doi: 10.3389/fneur.2018.00361. eCollection 2018. Review.

Myotonic dystrophy type 1: clinical manifestations in children and adolescents.
Ho G, Carey KA, Cardamone M, Farrar MA.
Arch Dis Child. 2018 Jun 5. pii: archdischild-2018-314837. doi: 10.1136/archdischild-2018-314837. [Epub ahead of print]

Relationships between Lower Limb Muscle Strength Impairments and Physical Limitations in DM1.
Petitclerc É, Hébert LJ, Mathieu J, Desrosiers J, Gagnon C.
J Neuromuscul Dis. 2018;5(2):215-224. doi: 10.3233/JND-170291.

Participation and the Role of Neuropsychological Functioning in Myotonic Dystrophy Type 1.
Van Heugten C, Meuleman S, Hellebrekers D, Kruitwagen-van Reenen E, Visser-Meily J.
J Neuromuscul Dis. 2018;5(2):205-214. doi: 10.3233/JND-170246.

Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy.
André LM, Ausems CRM, Wansink DG, Wieringa B.
Front Neurol. 2018 May 28;9:368. doi: 10.3389/fneur.2018.00368. eCollection 2018. Review.

Repeat-Associated Non-ATG Translation in Neurological Diseases.
Zu T, Pattamatta A, Ranum LPW.
Cold Spring Harb Perspect Biol. 2018 Jun 11. pii: a033019. doi: 10.1101/cshperspect.a033019. [Epub ahead of print]

Ankle Strength Impairments in Myotonic Dystrophy Type 1: A Five-Year Follow-up.
Hébert LJ, Vial C, Hogrel JY, Puymirat J.
J Neuromuscul Dis. 2018 Jun 4. doi: 10.3233/JND-180311. [Epub ahead of print]

Orofacial strength, dysarthria, and dysphagia in Congenital Myotonic Dystrophy.
Berggren KN, Hung M, Dixon MM, Bounsanga J, Crockett B, Foye MD, Gu Y, Campbell C, Butterfield RJ, Johnson NE.
Muscle Nerve. 2018 Jun 14. doi: 10.1002/mus.26176. [Epub ahead of print]

Recapitulating muscle disease phenotypes with myotonic dystrophy 1 iPS cells: a tool for disease modeling and drug discovery.
Mondragon-Gonzalez R, Perlingeiro RCR.
Dis Model Mech. 2018 Jun 13. pii: dmm.034728. doi: 10.1242/dmm.034728. [Epub ahead of print]

Myotonic dystrophy type 1: reasons to be OPTIMISTIC.
Gagnon C, Gallais B, Laberge L.
Lancet Neurol. 2018 Jun 18. pii: S1474-4422(18)30240-0. doi: 10.1016/S1474-4422(18)30240-0. [Epub ahead of print]

Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial.
Okkersen K, Jimenez-Moreno C, Wenninger S, Daidj F, Glennon J, Cumming S, Littleford R, Monckton DG, Lochmüller H, Catt M, Faber CG, Hapca A, Donnan PT, Gorman G, Bassez G, Schoser B, Knoop H, Treweek S, van Engelen BGM; OPTIMISTIC consortium.
Lancet Neurol. 2018 Jun 18. pii: S1474-4422(18)30203-5. doi: 10.1016/S1474-4422(18)30203-5. [Epub ahead of print]

Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells.
Dastidar S, Ardui S, Singh K, Majumdar D, Nair N, Fu Y, Reyon D, Samara E, Gerli MFM, Klein AF, De Schrijver W, Tipanee J, Seneca S, Tulalamba W, Wang H, Chai YC, In't Veld P, Furling D, Tedesco FS, Vermeesch JR, Joung JK, Chuah MK, VandenDriessche T.
Nucleic Acids Res. 2018 Jun 27. doi: 10.1093/nar/gky548. [Epub ahead of print]

miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models.
Cerro-Herreros E, Sabater-Arcis M, Fernandez-Costa JM, Moreno N, Perez-Alonso M, Llamusi B, Artero R.
Nat Commun. 2018 Jun 26;9(1):2482. doi: 10.1038/s41467-018-04892-4.

Exercise Biology of Neuromuscular Disorders.
Ng SY, Manta A, Ljubicic V.
Appl Physiol Nutr Metab. 2018 Jun 26. doi: 10.1139/apnm-2018-0229. [Epub ahead of print]

AFM nano-mechanical study of the beating profile of hiPSC-derived cardiomyocytes beating bodies WT and DM1.
Dinarelli S, Girasole M, Spitalieri P, Talarico RV, Murdocca M, Botta A, Novelli G, Mango R, Sangiuolo F, Longo G.
J Mol Recognit. 2018 May 10:e2725. doi: 10.1002/jmr.2725. [Epub ahead of print]

Maternal Genetic Disorders in Pregnancy.
Harris S, Vora NL.
Obstet Gynecol Clin North Am. 2018 Jun;45(2):249-265. doi: 10.1016/j.ogc.2018.01.010. Review.

Affinity capillary electrophoresis for identification of active drug candidates in myotonic dystrophy type 1.
Neaga IO, Hambye S, Bodoki E, Palmieri C, Ansseau E, Belayew A, Oprean R, Blankert B.
Anal Bioanal Chem. 2018 May 8. doi: 10.1007/s00216-018-1107-6. [Epub ahead of print]

Reduction of Cellular Nucleic Acid Binding Protein encoded by a Myotonic Dystrophy type 2 gene causes muscle atrophy.
Wei C, Stock L, Schneider-Gold C, Sommer C, Timchenko NA, Timchenko L.
Mol Cell Biol. 2018 May 7. pii: MCB.00649-17. doi: 10.1128/MCB.00649-17. [Epub ahead of print]

Alternative splicing analysis in human monocytes and macrophages reveals MBNL1 as major regulator.
Liu H, Lorenzini PA, Zhang F, Xu S, Wong MSM, Zheng J, Roca X.
Nucleic Acids Res. 2018 May 16. doi: 10.1093/nar/gky401. [Epub ahead of print]

Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.
Morriss GR, Rajapakshe K, Huang S, Coarfa C, Cooper TA.
Hum Mol Genet. 2018 May 16. doi: 10.1093/hmg/ddy192. [Epub ahead of print]

Study of anti-Müllerian hormone levels in patients with Myotonic Dystrophy Type 1. Preliminary results.
Ergoli M, Venditti M, Dotolo R, Picillo E, Minucci S, Politano L.
Acta Myol. 2017 Dec 1;36(4):199-202. eCollection 2017 Dec.

Core Clinical Phenotypes in Myotonic Dystrophies.
Wenninger S, Montagnese F, Schoser B.
Front Neurol. 2018 May 2;9:303. doi: 10.3389/fneur.2018.00303. eCollection 2018. Review.

Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1.
López-Morató M, Brook JD, Wojciechowska M.
Front Neurol. 2018 May 18;9:349. doi: 10.3389/fneur.2018.00349. eCollection 2018. Review.

A 9-year follow-up study of quantitative muscle strength changes in myotonic dystrophy type 1.
Gagnon C, Petitclerc É, Kierkegaard M, Mathieu J, Duchesne É, Hébert LJ.
J Neurol. 2018 May 21. doi: 10.1007/s00415-018-8898-4. [Epub ahead of print]

rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences.
Sellier C, Cerro-Herreros E, Blatter M, Freyermuth F, Gaucherot A, Ruffenach F, Sarkar P, Puymirat J, Udd B, Day JW, Meola G, Bassez G, Fujimura H, Takahashi MP, Schoser B, Furling D, Artero R, Allain FHT, Llamusi B, Charlet-Berguerand N.
Nat Commun. 2018 May 22;9(1):2009. doi: 10.1038/s41467-018-04370-x.

Qualitative and Quantitative Aspects of Pain in Patients with Myotonic Dystrophy Type 2.
van Vliet J, Tieleman AA, Verrips A, Timmerman H, van Dongen RTM, van Engelen BGM, Wilder-Smith OHG.
J Pain. 2018 Mar 27. pii: S1526-5900(18)30117-2. doi: 10.1016/j.jpain.2018.03.006. [Epub ahead of print]

Daunorubicin reduces MBNL1 titration by expanded CUG repeat RNA and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy.
Chakraborty M, Sellier C, Ney M, Villa P, Charlet-Berguerand N, Artero R, Llamusi B.
Dis Model Mech. 2018 Mar 21. pii: dmm.032557. doi: 10.1242/dmm.032557. [Epub ahead of print]

Rhythm Management in Myotonic Dystrophy: Progress but Unsettled Issues Remain.
Groh WJ.
Heart Rhythm. 2018 Apr 3. pii: S1547-5271(18)30335-7. doi: 10.1016/j.hrthm.2018.03.037. [Epub ahead of print]

Is going beyond Rasch analysis necessary to assess the construct validity of a motor function scale?
Guillot T, Roche S, Rippert P, Hamroun D, Iwaz J, Ecochard R, Vuillerot C; MFM study group.
Arch Phys Med Rehabil. 2018 Apr 3. pii: S0003-9993(18)30205-3. doi: 10.1016/j.apmr.2018.02.017. [Epub ahead of print]

Intron retention induced by microsatellite expansions as a disease biomarker.
Sznajder ŁJ, Thomas JD, Carrell EM, Reid T, McFarland KN, Cleary JD, Oliveira R, Nutter CA, Bhatt K, Sobczak K, Ashizawa T, Thornton CA, Ranum LPW, Swanson MS.
Proc Natl Acad Sci U S A. 2018 Apr 2. pii: 201716617. doi: 10.1073/pnas.1716617115. [Epub ahead of print]

Disruption of sleep-wake continuum in myotonic dystrophy type 1: Beyond conventional sleep staging.
Bonanni E, Carnicelli L, Crapanzano D, Maestri M, Simoncini C, Baldanzi S, Falorni M, Garbarino S, Mancuso M, Bonuccelli U, Siciliano G.
Neuromuscul Disord. 2018 Feb 12. pii: S0960-8966(17)31378-0. doi: 10.1016/j.nmd.2018.02.004. [Epub ahead of print]

Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy.
Wojciechowska M, Sobczak K, Kozlowski P, Sedehizadeh S, Wojtkowiak-Szlachcic A, Czubak K, Markus R, Lusakowska A, Kaminska A, Brook JD.
Sci Rep. 2018 Apr 12;8(1):5885. doi: 10.1038/s41598-018-24156-x.

Importance of three-dimensional speckle tracking in the assessment of left atrial and ventricular dysfunction in patients with myotonic dystrophy type 1.
Guedes H, Moreno N, Dos Santos RP, Marques L, Seabra D, Pereira A, Andrade A, Pinto P.
Rev Port Cardiol. 2018 Apr 9. pii: S0870-2551(17)30377-3. doi: 10.1016/j.repc.2017.10.011. [Epub ahead of print]

The MEF2 transcriptional target DMPK induces loss of sarcomere structure and cardiomyopathy.
Damanafshan A, Elzenaar I, Samson-Couterie B, van der Made I, Bourajjaj M, van den Hoogenhof MM, van Veen HA, Picavet DI, Beqqali A, Ehler E, De Windt LJ, Pinto YM, van Oort RJ.
Cardiovasc Res. 2018 Apr 10. doi: 10.1093/cvr/cvy091. [Epub ahead of print]

Unusual association of a unique CAG interruption in 5' of DM1 CTG repeats with intergenerational contractions and low somatic mosaicism.
Stéphanie T, Elodie D, Céline D, Alexis B, David G, Yann P; French Dm-Scope Consortium, Marie S, Jean-Paul B, Guillaume B, Geneviève G.
Hum Mutat. 2018 Apr 17. doi: 10.1002/humu.23531. [Epub ahead of print]

Repeat-Associated Non-ATG (RAN) Translation in Fuchs' Endothelial Corneal Dystrophy.
Soragni E, Petrosyan L, Rinkoski TA, Wieben ED, Baratz KH, Fautsch MP, Gottesfeld JM.
Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):1888-1896. doi: 10.1167/iovs.17-23265.

Myotonic Dystrophy and Developmental Regulation of RNA Processing.
Thomas JD, Oliveira R, Sznajder ŁJ, Swanson MS.
Compr Physiol. 2018 Mar 25;8(2):509-553. doi: 10.1002/cphy.c170002.

Accumulation of lipid peroxidation products in human myotonic dystrophic muscle.
Mishra SK, Menon NK, Mauldin C.
Neurol India. 1993 Apr-Jun;41(2):83-85.

Dysautonomia as Onset Symptom of Myotonic Dystrophy Type 2.
Rossi S, Romano A, Modoni A, Perna F, Rizzo V, Santoro M, Monforte M, Pieroni M, Luigetti M, Pomponi MG, Silvestri G.
Eur Neurol. 2018 Mar 13;79(3-4):166-170. doi: 10.1159/000487508. [Epub ahead of print]

The effect of dual chamber minimal ventricular pacing on paroxysmal atrial fibrillation incidence in Myotonic Dystrophy type 1 patients: a prospective, randomized, single-blind, crossover study.
Russo V, Papa AA, Rago A, Eng CC, Nigro G.
Heart Rhythm. 2018 Mar 7. pii: S1547-5271(18)30206-6. doi: 10.1016/j.hrthm.2018.03.008. [Epub ahead of print]

Mapping ligand binding pockets in ClC-1 channels through an integrated in silico and experimental approach using anthracene-9-carboxylic acid and niflumic acid.
Altamura C, Mangiatordi GF, Nicolotti O, Sahbani D, Farinato A, Leonetti F, Carratù MR, Conte D, Desaphy JF, Imbrici P.
Br J Pharmacol. 2018 Mar 3. doi: 10.1111/bph.14192. [Epub ahead of print]

Ubiquitination of MBNL1 Is Required for Its Cytoplasmic Localization and Function in Promoting Neurite Outgrowth.
Wang PY, Chang KT, Lin YM, Kuo TY, Wang GS.
Cell Rep. 2018 Feb 27;22(9):2294-2306. doi: 10.1016/j.celrep.2018.02.025.

Bachmann bundle pacing reduces atrial electromechanical delay in type 1 myotonic dystrophypatients.
Russo V, Rago A, Papa AA, Arena G, Politano L, Nigro G.
J Interv Card Electrophysiol. 2018 Feb 27. doi: 10.1007/s10840-018-0331-5. [Epub ahead of print]

Effect and impact of mechanical ventilation in myotonic dystrophy type 1: a prospective cohort study.
Boussaïd G, Prigent H, Laforet P, Raphaël JC, Annane D, Orlikowski D, Lofaso F.
Thorax. 2018 Mar 23. pii: thoraxjnl-2017-210610. doi: 10.1136/thoraxjnl-2017-210610. [Epub ahead of print]

The Role of AMPK in Neuromuscular Biology and Disease.
Dial AG, Ng SY, Manta A, Ljubicic V.
Trends Endocrinol Metab. 2018 Mar 20. pii: S1043-2760(18)30041-9. doi: 10.1016/j.tem.2018.02.010. [Epub ahead of print] Review.

Interatrial block to predict atrial fibrillation in myotonic dystrophy type 1.
Russo V, Papa AA, Rago A, Ciardiello C, Marano M, Proietti R, Politano L, Nigro G.
Neuromuscul Disord. 2018 Jan 31. pii: S0960-8966(17)31292-0. doi: 10.1016/j.nmd.2018.01.010. [Epub ahead of print]

Modelling the pathogenesis of Myotonic Dystrophy type 1 cardiac phenotype through human iPSC-derived cardiomyocytes.
Spitalieri P, Talarico RV, Caioli S, Murdocca M, Serafino A, Girasole M, Dinarelli S, Longo G, Pucci S, Botta A, Novelli G, Zona C, Mango R, Sangiuolo F.
J Mol Cell Cardiol. 2018 Mar 15. pii: S0022-2828(18)30083-X. doi: 10.1016/j.yjmcc.2018.03.012. [Epub ahead of print]

Evidence for a relatively high proportion of DM2 mutations in a large group of Polish patients.
Sulek A, Krysa W, Rajkiewicz M, Lusakowska A, Kaminska A, Nojszewska M, Zdzienicka E, Kubalska J, Rakowicz M, Szirkowiec W, Kwiecinski H, Zaremba J.
Neurol Neurochir Pol. 2018 Mar 7. pii: S0028-3843(17)30336-5. doi: 10.1016/j.pjnns.2018.02.008. [Epub ahead of print]

Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1.
Wahbi K, Porcher R, Laforêt P, Fayssoil A, Bécane HM, Lazarus A, Sochala M, Stojkovic T, Béhin A, Leonard-Louis S, Arnaud P, Furling D, Probst V, Babuty D, Pellieux S, Clementy N, Bassez G, Péréon Y, Eymard B, Duboc D.
JAMA Neurol. 2018 Feb 5. doi: 10.1001/jamaneurol.2017.4778. [Epub ahead of print]

Genotype and other determinants of respiratory function in myotonic dystrophy type 1.
Boussaïd G, Wahbi K, Laforet P, Eymard B, Stojkovic T, Behin A, Djillali A, Orlikowski D, Prigent H, Lofaso F.
Neuromuscul Disord. 2017 Dec 26. pii: S0960-8966(17)30524-2. doi: 10.1016/j.nmd.2017.12.011. [Epub ahead of print]

The Canadian Neuromuscular Disease Registry: Connecting patients to national and international research opportunities.
Wei Y, McCormick A, MacKenzie A, O'Ferrall E, Venance S, Mah JK, Selby K, McMillan HJ, Smith G, Oskoui M, Hogan G, McAdam L, Mabaya G, Hodgkinson V, Lounsberry J, Korngut L, Campbell C.
Paediatr Child Health. 2018 Feb;23(1):20-26. doi: 10.1093/pch/pxx125. Epub 2017 Dec 8.

Swallowing impairments in Amyotrophic Lateral Sclerosis and Myotonic Dystrophy type 1: Looking for the portrait of dysphagic patient in neuromuscular diseases.
Andrenelli E, Galli FL, Gesuita R, Skrami E, Logullo FO, Provinciali L, Capecci M, Ceravolo MG, Coccia M.
NeuroRehabilitation. 2018;42(1):93-102. doi: 10.3233/NRE-172272.

Increased EEG Theta Spectral Power in Sleep in Myotonic Dystrophy Type 1.
Cheung J, Ruoff C, Moore H, Hagerman KA, Perez J, Sakamuri S, Warby SC, Mignot E, Day J, Sampson J.
J Clin Sleep Med. 2018 Jan 30. pii: jc-17-00313. [Epub ahead of print]

Cross-sectional serum metabolomic study of multiple forms of muscular dystrophy.
Spitali P, Hettne K, Tsonaka R, Sabir E, Seyer A, Hemerik JBA, Goeman JJ, Picillo E, Ergoli M, Politano L, Aartsma-Rus A.
J Cell Mol Med. 2018 Feb 14. doi: 10.1111/jcmm.13543. [Epub ahead of print]

A 34-year longitudinal study on long-term cardiac outcomes in DM1 patients with normal ECG at baseline at an Italian clinical centre.
Bucci E, Testa M, Licchelli L, Frattari A, El Halabieh NA, Gabriele E, Pignatelli G, De Santis T, Fionda L, Vanoli F, Morino S, Garibaldi M, Di Pasquale A, Vanacore N, Botta A, Antonini G.
J Neurol. 2018 Feb 10. doi: 10.1007/s00415-018-8773-3. [Epub ahead of print]

Craniofacial morphology and growth in young patients with congenital or childhood onset myotonic dystrophy.
Fontinha C, Engvall M, Sjögreen L, Kiliaridis S.
Eur J Orthod. 2018 Feb 6. doi: 10.1093/ejo/cjx104. [Epub ahead of print]

TALEN-Induced Double-Strand Break Repair of CTG Trinucleotide Repeats.
Mosbach V, Poggi L, Viterbo D, Charpentier M, Richard GF.
Cell Rep. 2018 Feb 20;22(8):2146-2159. doi: 10.1016/j.celrep.2018.01.083.

Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness.
Omori Y, Kanbayashi T, Imanishi A, Tsutsui K, Sagawa Y, Kikuchi YS, Takeshima M, Yoshizawa K, Uemura S, Shimizu T.
Neuropsychiatr Dis Treat. 2018 Feb 8;14:451-457. doi: 10.2147/NDT.S158651. eCollection 2018.

An engineered RNA binding protein with improved splicing regulation.
Hale MA, Richardson JI, Day RC, McConnell OL, Arboleda J, Wang ET, Berglund JA.
Nucleic Acids Res. 2018 Jan 4. doi: 10.1093/nar/gkx1304. [Epub ahead of print]

Altered levels of the splicing factor muscleblind modifies cerebral cortical function in mouse models of myotonic dystrophy.
Chen G, Carter RE, Cleary JD, Reid TS, Ranum LP, Swanson MS, Ebner TJ.
Neurobiol Dis. 2018 Jan 10. pii: S0969-9961(18)30003-2. doi: 10.1016/j.nbd.2018.01.003. [Epub ahead of print]

Childhood-onset form of myotonic dystrophy type 1 and autism spectrum disorder: Is there comorbidity?
Angeard N, Huerta E, Jacquette A, Cohen D, Xavier J, Gargiulo M, Servais L, Eymard B, Héron D.
Neuromuscul Disord. 2017 Dec 15. pii: S0960-8966(17)31337-8. doi: 10.1016/j.nmd.2017.12.006. [Epub ahead of print]

The Frequency and Risk Factors for Ischemic Stroke in Myotonic Dystrophy Type 1 Patients.
Yoshida K, Aburakawa Y, Suzuki Y, Kuroda K, Kimura T.
J Stroke Cerebrovasc Dis. 2018 Jan 3. pii: S1052-3057(17)30592-X. doi: 10.1016/j.jstrokecerebrovasdis.2017.10.030. [Epub ahead of print]

Relationships between grip strength, myotonia, and CTG expansion in myotonic dystrophy type 1.
Hogrel JY, Ollivier G, Ledoux I, Hébert LJ, Eymard B, Puymirat J, Bassez G.
Ann Clin Transl Neurol. 2017 Nov 7;4(12):921-925. doi: 10.1002/acn3.496. eCollection 2017 Dec.

Expanded [CCTG]n repetitions are not associated with abnormal methylation at the CNBP locus in myotonic dystrophy type 2 (DM2) patients.
Santoro M, Fontana L, Maiorca F, Centofanti F, Massa R, Silvestri G, Novelli G, Botta A.
Biochim Biophys Acta. 2017 Dec 29;1864(3):917-924. doi: 10.1016/j.bbadis.2017.12.037. [Epub ahead of print]

Mitochondrial dysfunction in myotonic dystrophy type 1.
Gramegna LL, Giannoccaro MP, Manners DN, Testa C, Zanigni S, Evangelisti S, Bianchini C, Oppi F, Poda R, Avoni P, Lodi R, Liguori R, Tonon C.
Neuromuscul Disord. 2017 Nov 14. pii: S0960-8966(17)30211-0. doi: 10.1016/j.nmd.2017.10.007. [Epub ahead of print]

Reliability of the Apathy Evaluation Scale in Myotonic Dystrophy Type 1.
Gallais B.
J Neuromuscul Dis. 2017 Dec 20. doi: 10.3233/JND-170274. [Epub ahead of print]

Selective alkylation of T-T mismatched DNA using vinyldiaminotriazine-acridine conjugate.
Onizuka K, Usami A, Yamaoki Y, Kobayashi T, Hazemi ME, Chikuni T, Sato N, Sasaki K, Katahira M, Nagatsugi F.
Nucleic Acids Res. 2018 Jan 4. doi: 10.1093/nar/gkx1278. [Epub ahead of print]

An engineered RNA binding protein with improved splicing regulation.
Hale MA, Richardson JI, Day RC, McConnell OL, Arboleda J, Wang ET, Berglund JA.
Nucleic Acids Res. 2018 Jan 4. doi: 10.1093/nar/gkx1304. [Epub ahead of print]

Design of 'Mini' Nucleic Acid Probe for Cooperative Binding of RNA-Repeated Transcript Associated with Myotonic Dystrophy Type 1.
Hsieh WC, Bahal R, Thadke S, Bhatt K, Sobczak K, Thornton CA, Ly DH.
Biochemistry. 2018 Jan 15. doi: 10.1021/acs.biochem.7b01239. [Epub ahead of print]

Altered levels of the splicing factor muscleblind modifies cerebral cortical function in mouse models of myotonic dystrophy.
Chen G, Carter RE, Cleary JD, Reid TS, Ranum LP, Swanson MS, Ebner TJ.
Neurobiol Dis. 2018 Jan 10. pii: S0969-9961(18)30003-2. doi: 10.1016/j.nbd.2018.01.003. [Epub ahead of print]

Myotonic Dystrophy Patient Preferences in Patient-Reported Outcome Measures.
Heatwole C, Johnson N, Dekdebrun J, Dilek N, Eichinger K, Hilbert J, Luebbe E, Martens W, McDermott MP, Thornton C, Moxley R.
Muscle Nerve. 2018 Jan 12. doi: 10.1002/mus.26066. [Epub ahead of print]

Speech characteristics in the congenital and childhood-onset forms of myotonic dystrophy type 1.
Sjögreen L, Mårtensson Å, Ekström AB.
Int J Lang Commun Disord. 2018 Jan 12. doi: 10.1111/1460-6984.12370. [Epub ahead of print]

R-loops: targets for nuclease cleavage and repeat instability.
Freudenreich CH.
Curr Genet. 2018 Jan 11. doi: 10.1007/s00294-018-0806-z. [Epub ahead of print] Review.

Repeat expansion diseases.
Paulson H.
Handb Clin Neurol. 2018;147:105-123. doi: 10.1016/B978-0-444-63233-3.00009-9.

RNA-Templated Concatenation of Triplet Nucleic Acid Probe.
Ly DH, Bahal R, Manna A, Hsieh WC, Thadke SA, Sureshkumar G.
Chembiochem. 2018 Jan 11. doi: 10.1002/cbic.201700574. [Epub ahead of print]

Preimplantation Genetic Diagnosis for Myotonic Dystrophy Type 1 and Analysis of the Effect of the Disease on the Reproductive Outcome of the Affected Female Patients.
Fernández RM, Lozano-Arana MD, Sánchez B, Peciña A, García-Lozano JC, Borrego S, Antiñolo G.
Biomed Res Int. 2017;2017:9165363. doi: 10.1155/2017/9165363. Epub 2017 Nov 14.

A More Efficient Transportable and Scalable System for Real-Time Activities and Exercises Recognition.
Chapron K, Plantevin V, Thullier F, Bouchard K, Duchesne E, Gaboury S.
Sensors (Basel). 2018 Jan 18;18(1). pii: E268. doi: 10.3390/s18010268.

Altered power spectral density in the resting-state sensorimotor network in patients with myotonic dystrophy type 1.
Park JS, Seo J, Cha H, Song HJ, Lee SH, Jang KE, Lee HJ, Park J, Lee HW, Chang Y.
Sci Rep. 2018 Jan 17;8(1):987. doi: 10.1038/s41598-018-19217-0.

Hearing impairment in patients with myotonic dystrophy type 2.
van Vliet J, Tieleman AA, van Engelen BGM, Bassez G, Servais L, Béhin A, Stojkovic T, Meulstee J, Engel JAM, Lamas G, Eymard B, Verhagen WIM, Mamelle E.
Neurology. 2018 Jan 17. pii: 10.1212/WNL.0000000000004963. doi: 10.1212/WNL.0000000000004963. [Epub ahead of print]

Macroscopic and microscopic diversity of missplicing in the central nervous system of patients with myotonic dystrophy type 1.
Furuta M, Kimura T, Nakamori M, Matsumura T, Fujimura H, Jinnai K, Takahashi MP, Mochizuki H, Yoshikawa H.
Neuroreport. 2018 Feb 7;29(3):235-240. doi: 10.1097/WNR.0000000000000968.

Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.
De Bellis M, Sanarica F, Carocci A, Lentini G, Pierno S, Rolland JF, Conte Camerino D, De Luca A.
Front Pharmacol. 2018 Jan 12;8:907. doi: 10.3389/fphar.2017.00907. eCollection 2017.

Childhood-onset form of myotonic dystrophy type 1 and autism spectrum disorder: Is there comorbidity?
Angeard N, Huerta E, Jacquette A, Cohen D, Xavier J, Gargiulo M, Servais L, Eymard B, Héron D.
Neuromuscul Disord. 2017 Dec 15. pii: S0960-8966(17)31337-8. doi: 10.1016/j.nmd.2017.12.006. [Epub ahead of print]

Falls and resulting fractures in Myotonic Dystrophy: Results from a multinational retrospective survey.
Jiménez-Moreno AC, Raaphorst J, Babačić H, Wood L, van Engelen B, Lochmüller H, Schoser B, Wenninger S.
Neuromuscul Disord. 2017 Dec 27. pii: S0960-8966(17)31403-7. doi: 10.1016/j.nmd.2017.12.010. [Epub ahead of print]

Anesthetic Management for Multiple Family Members with Myotonic Dystrophy for Interventional Cardiac Procedures-A Case Series.
Gorelik L, Flores A.
Front Med (Lausanne). 2018 Jan 8;4:243. doi: 10.3389/fmed.2017.00243. eCollection 2017.

Responsiveness of performance-based outcome measures for mobility, balance, muscle strength and manual dexterity in adults with myotonic dystrophy type 1.
Kierkegaard M, Petitclerc É, Hébert LJ, Mathieu J, Gagnon C.
J Rehabil Med. 2017 Dec 20. doi: 10.2340/16501977-2304. [Epub ahead of print]

Correction of GSK3β at young age prevents muscle pathology in mice with myotonic dystrophytype 1.
Wei C, Stock L, Valanejad L, Zalewski ZA, Karns R, Puymirat J, Nelson D, Witte D, Woodgett J, Timchenko NA, Timchenko L.
FASEB J. 2017 Dec 4. pii: fj.201700700R. doi: 10.1096/fj.201700700R. [Epub ahead of print]

Hybrid splicing minigene and antisense oligonucleotides as efficient tools to determine functional protein/RNA interactions.
Cywoniuk P, Taylor K, Sznajder ŁJ, Sobczak K.
Sci Rep. 2017 Dec 14;7(1):17587. doi: 10.1038/s41598-017-17816-x.

CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients.
Provenzano C, Cappella M, Valaperta R, Cardani R, Meola G, Martelli F, Cardinali B, Falcone G.
Mol Ther Nucleic Acids. 2017 Dec 15;9:337-348. doi: 10.1016/j.omtn.2017.10.006. Epub 2017 Oct 14.

Lymphoblastoids cell lines - Derived iPSC line from a 26-year-old myotonic dystrophy type 1 patient carrying (CTG)<sub>200</sub> expansion in the DMPK gene: CHUQi001-A.
Martineau L, Racine V, Benichou SA, Puymirat J.
Stem Cell Res. 2017 Dec 16;26:103-106. doi: 10.1016/j.scr.2017.12.010. [Epub ahead of print]

Minimizing carry-over PCR contamination in expanded CAG/CTG repeat instability applications.
Aeschbach L, Dion V.
Sci Rep. 2017 Dec 21;7(1):18026. doi: 10.1038/s41598-017-18168-2.

The competing mini-dumbbell mechanism: new insights into CCTG repeat expansion.
Guo P, Lam SL.
Signal Transduct Target Ther. 2016 Dec 2;1:16028. doi: 10.1038/sigtrans.2016.28. eCollection 2016.

The relative frequency of common neuromuscular diagnoses in a reference center.
Cotta A, Paim JF, Carvalho E, da-Cunha-Júnior AL, Navarro MM, Valicek J, Menezes MM, Nunes SV, Xavier-Neto R, Baptista S Junior, Lima LR, Takata RI, Vargas AP.
Arq Neuropsiquiatr. 2017 Nov;75(11):789-795. doi: 10.1590/0004-282X20170151.

Cardiac involvement in myotonic dystrophy: The role of troponins and N-terminal pro B-type natriuretic peptide.
Valaperta R, De Siena C, Cardani R, Lombardia F, Cenko E, Rampoldi B, Fossati B, Brigonzi E, Rigolini R, Gaia P, Meola G, Costa E, Bugiardini R.
Atherosclerosis. 2017 Oct 21;267:110-115. doi: 10.1016/j.atherosclerosis.2017.10.020. [Epub ahead of print]
 
Risk of skin cancer among patients with myotonic dystrophy type 1 based on Primary care physician data from the United Kingdom Clinical Practice Research Datalink.
Wang Y, Pfeiffer RM, Alsaggaf R, Meeraus W, Gage JC, Anderson LA, Bremer RC, Nikolenko N, Lochmuller H, Greene MH, Gadalla SM.
Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31143. [Epub ahead of print]
 
Cardiac autonomic control during sleep in patients with myotonic dystrophy type 1: the effects of comorbid obstructive sleep apnea.
Tobaldini E, Colombo G, Solbiati M, Cogliati C, Morandi L, Pincherle A, Montano N.
Sleep Med. 2017 Nov;39:32-37. doi: 10.1016/j.sleep.2017.07.023.

Nanopore sequencing of complex genomic rearrangements in yeast reveals mechanisms of repeat-mediated double-strand break repair.
McGinty RJ, Rubinstein RG, Neil AJ, Dominska M, Kiktev D, Petes TD, Mirkin SM.
Genome Res. 2017 Nov 7. pii: gr.228148.117. doi: 10.1101/gr.228148.117. [Epub ahead of print]

Cognitive impairment and quality of life in patients with myotonic dystrophy type 1.
Fujino H, Shingaki H, Suwazono S, Ueda Y, Wada C, Nakayama T, Takahashi MP, Imura O, Matsumura T.
Muscle Nerve. 2017 Nov 28. doi: 10.1002/mus.26022. [Epub ahead of print]

Imaging of the thymus in myotonic dystrophy type 1.
Mignarri A, Gentili F, Masia F, Genua A, Cenciarelli S, Brunori P, Mazzei MA, Malandrini A, Federico A, Mazzei FG, Dotti MT.
Neurol Sci. 2017 Nov 25. doi: 10.1007/s10072-017-3202-4. [Epub ahead of print]

Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9.
Pinto BS, Saxena T, Oliveira R, Méndez-Gómez HR, Cleary JD, Denes LT, McConnell O, Arboleda J, Xia G, Swanson MS, Wang ET.
Mol Cell. 2017 Oct 18. pii: S1097-2765(17)30711-6. doi: 10.1016/j.molcel.2017.09.033. [Epub ahead of print]

Aberrant Myokine Signaling in Congenital Myotonic Dystrophy.
Nakamori M, Hamanaka K, Thomas JD, Wang ET, Hayashi YK, Takahashi MP, Swanson MS, Nishino I, Mochizuki H.
Cell Rep. 2017 Oct 31;21(5):1240-1252. doi: 10.1016/j.celrep.2017.10.018.

Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2.
Montagnese F, Mondello S, Wenninger S, Kress W, Schoser B.
J Neurol. 2017 Oct 30. doi: 10.1007/s00415-017-8653-2. [Epub ahead of print]

Genome engineering: a new approach to gene therapy for neuromuscular disorders.
Nelson CE, Robinson-Hamm JN, Gersbach CA.
Nat Rev Neurol. 2017 Sep 29. doi: 10.1038/nrneurol.2017.126. [Epub ahead of print] 

MBNL expression in autoregulatory feedback loops.
Konieczny P, Stepniak-Konieczna E, Sobczak K.
RNA Biol. 2017 Sep 26:0. doi: 10.1080/15476286.2017.1384119. [Epub ahead of print]

Genetic testing of individuals with pre-senile cataract identifies patients with myotonic dystrophytype 2.
Rakočević-Stojanović V, Perić S, Pešović J, Senćanić I, Božić M, Šviković S, Brkušanin M, Savić-Pavićević D.
Eur J Neurol. 2017 Nov;24(11):e79-e80. doi: 10.1111/ene.13401.

Reduced renal function in patients with Myotonic Dystrophy type 1 and the association to CTG expansion and other potential risk factors for chronic kidney disease.
Aldenbratt A, Lindberg C, Svensson MK.
Neuromuscul Disord. 2017 Aug 15. pii: S0960-8966(17)30212-2. doi: 10.1016/j.nmd.2017.08.002. [Epub ahead of print]

Detection of expanded RNA repeats using thermostable group II intron reverse transcriptase.
Carrell ST, Tang Z, Mohr S, Lambowitz AM, Thornton CA.
Nucleic Acids Res. 2017 Oct 3. doi: 10.1093/nar/gkx867. [Epub ahead of print]

Origin of the myotonic dystrophy type 1 mutation in Mexican population and influence of Amerindian ancestry on CTG repeat allelic distribution.
Murillo-Melo NM, Márquez-Quiróz LC, Gómez R, Orozco L, Mendoza-Caamal E, Tapia-Guerrero YS, Camacho-Mejorado R, Cortés H, López-Reyes A, Santana C, Noris G, Hernández-Hernández O, Cisneros B, Magaña JJ.
Neuromuscul Disord. 2017 Sep 21. pii: S0960-8966(16)31076-8. doi: 10.1016/j.nmd.2017.09.004. [Epub ahead of print]

French translation and cross-cultural adaptation of the Myotonic Dystrophy Health Index (MDHI).
Gagnon C, Tremblay M, Côté I, Heatwole C.
Muscle Nerve. 2017 Oct 20. doi: 10.1002/mus.25994. [Epub ahead of print]

Measuring Dynamic Behavior of Trinucleotide Repeat Tracts In Vivo in Saccharomyces cerevisiae.
Williams GM, Surtees JA.
Methods Mol Biol. 2018;1672:439-470. doi: 10.1007/978-1-4939-7306-4_30.

Small molecule alteration of RNA sequence in cells and animals.
Guan L, Luo Y, Ja WW, Disney MD.
Bioorg Med Chem Lett. 2017 Oct 18. pii: S0960-894X(17)31018-1. doi: 10.1016/j.bmcl.2017.10.034. [Epub ahead of print]

Lower limb muscle magnetic resonance imaging in myotonic dystrophy type 1 correlates with the six-minute walk test and CTG repeats.
Park D, Lee SH, Shin JH, Park JS.
Neuromuscul Disord. 2017 Aug 24. pii: S0960-8966(17)30350-4. doi: 10.1016/j.nmd.2017.08.005. [Epub ahead of print]

Brain gray matter structural network in myotonic dystrophy type 1.
Sugiyama A, Sone D, Sato N, Kimura Y, Ota M, Maikusa N, Maekawa T, Enokizono M, Mori-Yoshimura M, Ohya Y, Kuwabara S, Matsuda H.
PLoS One. 2017 Nov 2;12(11):e0187343. doi: 10.1371/journal.pone.0187343. eCollection 2017.

RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2.
Zu T, Cleary JD, Liu Y, Bañez-Coronel M, Bubenik JL, Ayhan F, Ashizawa T, Xia G, Clark HB, Yachnis AT, Swanson MS, Ranum LPW.
Neuron. 2017 Sep 13;95(6):1292-1305.e5. doi: 10.1016/j.neuron.2017.08.039.
 
The cognitive profile of myotonic dystrophy type 1: A systematic review and meta-analysis.
Okkersen K, Buskes M, Groenewoud J, Kessels RPC, Knoop H, van Engelen B, Raaphorst J.
Cortex. 2017 Aug 16;95:143-155. doi: 10.1016/j.cortex.2017.08.008. [Epub ahead of print] Review.
 
Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle.
Renna LV, Bosè F, Iachettini S, Fossati B, Saraceno L, Milani V, Colombo R, Meola G, Cardani R.
PLoS One. 2017 Sep 15;12(9):e0184987. doi: 10.1371/journal.pone.0184987. 

Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
Mootha VV, Hansen B, Rong Z, Mammen PP, Zhou Z, Xing C, Gong X.
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4579-4585. doi: 10.1167/iovs.17-22350.

The Myotonic Dystrophy Health Index: Italian validation of a disease-specific outcome measure.
Sansone VA, Lizio A, Greco L, Gragnano G, Zanolini A, Gualandris M, Iatomasi M, Heatwole C.
Neuromuscul Disord. 2017 Jul 10. pii: S0960-8966(17)30384-X. doi: 10.1016/j.nmd.2017.07.004. [Epub ahead of print]

Sarcolemmal excitability in the myotonic dystrophies.
Boland-Freitas R, Lee J, Howells J, Liang C, Corbett A, Nicholson G, Ng K.
Muscle Nerve. 2017 Sep 7. doi: 10.1002/mus.25962. [Epub ahead of print]

Global muscular dystrophy research: A 25-year bibliometric perspective.
Ram S.
Neurol India. 2017 Sep-Oct;65(5):993-1000. doi: 10.4103/neuroindia.NI_1241_16. Review.

CELF1 Mediates Connexin 43 mRNA Degradation in Dilated Cardiomyopathy.
Chang KT, Cheng CF, King PC, Liu SY, Wang GS.
Circ Res. 2017 Sep 5. pii: CIRCRESAHA.117.311281. doi: 10.1161/CIRCRESAHA.117.311281. [Epub ahead of print]
Palliative care in neuromuscular diseases.
de Visser M, Oliver DJ.
Curr Opin Neurol. 2017 Sep 13. doi: 10.1097/WCO.0000000000000493. [Epub ahead of print]

Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions.
Pešović J, Perić S, Brkušanin M, Brajušković G, Rakočević-Stojanović V, Savić-Pavićević D.
Neurogenetics. 2017 Sep 23. doi: 10.1007/s10048-017-0523-7. [Epub ahead of print]

Brain imaging in myotonic dystrophy type 1: A systematic review.
Okkersen K, Monckton DG, Le N, Tuladhar AM, Raaphorst J, van Engelen BGM.
Neurology. 2017 Aug 2. pii: 10.1212/WNL.0000000000004300. doi: 10.1212/WNL.0000000000004300. [Epub ahead of print] Review.

High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.
Hilbert JE, Barohn RJ, Clemens PR, Luebbe EA, Martens WB, McDermott MP, Parkhill AL, Tawil R, Thornton CA, Moxley RT 3rd; National Registry Scientific Advisory Committee/Investigators.
Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004420. doi: 10.1212/WNL.0000000000004420. [Epub ahead of print]

Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study.
Baldanzi S, Bevilacqua F, Lorio R, Volpi L, Simoncini C, Petrucci A, Cosottini M, Massimetti G, Tognoni G, Ricci G, Angelini C, Siciliano G.
Orphanet J Rare Dis. 2016 Apr 4;11:34. doi: 10.1186/s13023-016-0417-z.

Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9.
Batra R, Nelles DA, Pirie E, Blue SM, Marina RJ, Wang H, Chaim IA, Thomas JD, Zhang N, Nguyen V, Aigner S, Markmiller S, Xia G, Corbett KD, Swanson MS, Yeo GW.
Cell. 2017 Aug 8. pii: S0092-8674(17)30817-6. doi: 10.1016/j.cell.2017.07.010. [Epub ahead of print]

Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies.
Peric S, Maksimovic R, Banko B, Durdic M, Bjelica B, Bozovic I, Balcik Y, Pesovic J, Savic-Pavicevic D, Rakocevic-Stojanovic V.
J Neurol. 2017 Jul 29. doi: 10.1007/s00415-017-8574-0. [Epub ahead of print]

Myotonic dystrophy: candidate small molecule therapeutics.
Konieczny P, Selma-Soriano E, Rapisarda AS, Fernandez-Costa JM, Perez-Alonso M, Artero R.
Drug Discov Today. 2017 Aug 2. pii: S1359-6446(17)30132-0. doi: 10.1016/j.drudis.2017.07.011. [Epub ahead of print]

Myotonic Dystrophy Type 1 Clinical, Electrophysiological and Molecular Characterization: Experience at Tertiary Care Centre.
Khadilkar S, Jagiasi K, Yadav J, Chavan SV, Soni G, Patel B.
J Assoc Physicians India. 2017 Jun;65(6):32-37.

Clinical characteristics of pregnancies complicated by congenital myotonic dystrophy.
Yee C, Choi SJ, Oh SY, Ki CS, Roh CR, Kim JH.
Obstet Gynecol Sci. 2017 Jul;60(4):323-328. doi: 10.5468/ogs.2017.60.4.323. Epub 2017 Jul 14.

Evolving Motivations: Patients' and Caregivers' Perceptions About Seeking Myotonic Dystrophy (DM1) and Huntington's Disease Care.
LaDonna KA, Watling CJ, Ray SL, Piechowicz C, Venance SL.
Qual Health Res. 2017 Sep;27(11):1727-1737. doi: 10.1177/1049732317711901. Epub 2017 Jun 19.

BNA<sup>NC</sup> gapmers revert splicing and reduce RNA foci with low toxicity in myotonic dystrophy cells.
Manning KS, Rao AN, Castro M, Cooper TA.
ACS Chem Biol. 2017 Aug 30. doi: 10.1021/acschembio.7b00416. [Epub ahead of print]

RNA biology of disease-associated microsatellite repeat expansions.
Rohilla KJ, Gagnon KT.
Acta Neuropathol Commun. 2017 Aug 29;5(1):63. doi: 10.1186/s40478-017-0468-y.

Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9.
Batra R, Nelles DA, Pirie E, Blue SM, Marina RJ, Wang H, Chaim IA, Thomas JD, Zhang N, Nguyen V, Aigner S, Markmiller S, Xia G, Corbett KD, Swanson MS, Yeo GW.
Cell. 2017 Aug 8. pii: S0092-8674(17)30817-6. doi: 10.1016/j.cell.2017.07.010. [Epub ahead of print]

Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies.
Peric S, Maksimovic R, Banko B, Durdic M, Bjelica B, Bozovic I, Balcik Y, Pesovic J, Savic-Pavicevic D, Rakocevic-Stojanovic V.
J Neurol. 2017 Jul 29. doi: 10.1007/s00415-017-8574-0. [Epub ahead of print]

Myotonic dystrophy: candidate small molecule therapeutics.
Konieczny P, Selma-Soriano E, Rapisarda AS, Fernandez-Costa JM, Perez-Alonso M, Artero R.
Drug Discov Today. 2017 Aug 2. pii: S1359-6446(17)30132-0. doi: 10.1016/j.drudis.2017.07.011. [Epub ahead of print]

Myotonic Dystrophy Type 1 Clinical, Electrophysiological and Molecular Characterization: Experience at Tertiary Care Centre.
Khadilkar S, Jagiasi K, Yadav J, Chavan SV, Soni G, Patel B.
J Assoc Physicians India. 2017 Jun;65(6):32-37.

Clinical characteristics of pregnancies complicated by congenital myotonic dystrophy.
Yee C, Choi SJ, Oh SY, Ki CS, Roh CR, Kim JH.
Obstet Gynecol Sci. 2017 Jul;60(4):323-328. doi: 10.5468/ogs.2017.60.4.323. Epub 2017 Jul 14.

Evolving Motivations: Patients' and Caregivers' Perceptions About Seeking Myotonic Dystrophy (DM1) and Huntington's Disease Care.
LaDonna KA, Watling CJ, Ray SL, Piechowicz C, Venance SL.
Qual Health Res. 2017 Sep;27(11):1727-1737. doi: 10.1177/1049732317711901. Epub 2017 Jun 19.

BNANC gapmers revert splicing and reduce RNA foci with low toxicity in myotonic dystrophy cells.
Manning KS, Rao AN, Castro M, Cooper TA.ACS
Chem Biol. 2017 Aug 30. doi: 10.1021/acschembio.7b00416. [Epub ahead of print]

RNA biology of disease-associated microsatellite repeat expansions.
Rohilla KJ, Gagnon KT.Acta
Neuropathol Commun. 2017 Aug 29;5(1):63. doi: 10.1186/s40478-017-0468-y.

Disrupted prenatal RNA processing and myogenesis in congenital myotonic dystrophy.
Thomas JD, Sznajder LJ, Bardhi O, Aslam FN, Anastasiadis ZP, Scotti MM, Nishino I, Nakamori M, Wang ET, Swanson MS.
Genes Dev. 2017 Jul 11. doi: 10.1101/gad.300590.117. [Epub ahead of print]

The proposal of a clinical protocol to assess central and peripheral fatigue in myotonic dystrophy type 1.
Baldanzi S, Ricci G, Bottari M, Chico L, Simoncini C, Siciliano G.
Arch Ital Biol. 2017 Jul 1;155(1-2):43-54. doi: 10.12871/000398292017125.

Cutaneous manifestations in Steinert’s disease. Apropos of four clinical cases.
Cona F, Lotti J, Fioranelli M, Roccia MG, Lotti T, Guarneri C.
J Biol Regul Homeost Agents. 2017 Jul 13;31(2 Suppl. 2). [Epub ahead of print]

Personality traits in patients with myotonic dystrophy type 2.
Paunic T, Peric S, Parojcic A, Savic-Pavicevic D, Vujnic M, Pesovic J, Basta I, Lavrnic D, Rakocevic-Stojanovic V.
Acta Myol. 2017 Mar;36(1):14-18.

Investigation of the molecular mechanisms underlying myotonic dystrophy types 1 and 2 cataracts using microRNA target gene networks.
Shao D, Zhu X, Sun W, Huo L, Chen W, Wang H, Liu B, Pan P.
Mol Med Rep. 2017 Jul 21. doi: 10.3892/mmr.2017.7059. [Epub ahead of print]

Structural basis for interaction of the tandem zinc finger domains of human muscleblind with cognate RNA from human cardiac troponin T.
Park S, Phukan PD, Zeeb M, Martinez-Yamout MA, Dyson HJ, Wright PE.
Biochemistry. 2017 Jul 18. doi: 10.1021/acs.biochem.7b00484. [Epub ahead of print]

Congenital myotonic dystrophy-an RNA-mediated disease across a developmental continuum.
Jagannathan S, Bradley RK.
Genes Dev. 2017 Jun 1;31(11):1067-1068. doi: 10.1101/gad.302893.117.

Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.
Jauvin D, Chrétien J, Pandey SK, Martineau L, Revillod L, Bassez G, Lachon A, McLeod AR, Gourdon G, Wheeler TM, Thornton CA, Bennett CF, Puymirat J.
Mol Ther Nucleic Acids. 2017 Jun 16;7:465-474. doi: 10.1016/j.omtn.2017.05.007. Epub 2017 May 17.

Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes.
Cerro-Herreros E, Chakraborty M, Pérez-Alonso M, Artero R, Llamusí B.
Sci Rep. 2017 Jun 6;7(1):2843. doi: 10.1038/s41598-017-02829-3.

Association Between Mutation Size and Cardiac Involvement in Myotonic Dystrophy Type 1: An Analysis of the DM1-Heart Registry.
Chong-Nguyen C, Wahbi K, Algalarrondo V, Bécane HM, Radvanyi-Hoffman H, Arnaud P, Furling D, Lazarus A, Bassez G, Béhin A, Fayssoil A, Laforêt P, Stojkovic T, Eymard B, Duboc D.
Circ Cardiovasc Genet. 2017 Jun;10(3). pii: e001526. doi: 10.1161/CIRCGENETICS.116.001526.

In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL, Konieczny P, Llamusi B, Delgado-Pinar E, Borrell JI, Teixidó J, García-España E, Pérez-Alonso M, Estrada-Tejedor R, Artero R.
PLoS One. 2017 Jun 5;12(6):e0178931. doi: 10.1371/journal.pone.0178931.

Brain positron emission tomography in patients with myotonic dystrophy type 1 and type 2.
Peric S, Brajkovic L, Belanovic B, Ilic V, Salak-Djokic B, Basta I, Rakocevic Stojanovic V.
J Neurol Sci. 2017 Jul 15;378:187-192. doi: 10.1016/j.jns.2017.05.013. Epub 2017 May 10.

Noninvasive assessment of respiratory muscle strength and activity in Myotonic dystrophy.
Evangelista MA, Dias FAL, Dourado Júnior MET, do Nascimento GC, Sarmento A, Gualdi LP, Aliverti A, Resqueti V, Fregonezi GAF.
PLoS One. 2017 Jun 8;12(6):e0177318. doi: 10.1371/journal.pone.0177318.

Risk for Complications after Pacemaker or Cardioverter Defibrillator Implantations in Patients with Myotonic Dystrophy Type 1.
Sochala M, Wahbi K, Sorbets E, Lazarus A, Bécane HM, Stojkovic T, Fayssoil A, Laforêt P, Béhin A, Sroussi M, Eymard B, Duboc D, Meune C.
J Neuromuscul Dis. 2017 Jun 6. doi: 10.3233/JND-170232. [Epub ahead of print]

Routine echocardiography in patients with myotonic dystrophy type 1.
Paunic T, Peric S, Cvitan E, Raspopovic S, Peric M, Mandic Stojmenovic G, Rakocevic Stojanovic V.
J Chin Med Assoc. 2017 Jun 7. pii: S1726-4901(17)30104-1. doi: 10.1016/j.jcma.2017.04.004. [Epub ahead of print]

Temporomandibular dysfunction in adult patients with myotonic dystrophy (DM1).
Mejersjö C, Kiliaridis S.
J Oral Rehabil. 2017 Jun 10. doi: 10.1111/joor.12534. [Epub ahead of print]

(CCUG)n RNA toxicity in a Drosophila model for myotonic dystrophy type 2 (DM2) activates apoptosis.
Yenigun VB, Sirito M, Amcheslavky A, Czernuszewicz T, Colonques-Bellmunt J, García-Alcover I, Wojciechowska M, Bolduc C, Chen Z, López Castel A, Krahe R, Bergmann A.
Dis Model Mech. 2017 Jun 16. pii: dmm.026179. doi: 10.1242/dmm.026179. [Epub ahead of print]

Dissecting the benefits of long-term non-invasive ventilation in patients with distinct neuromuscular disorders.
Boentert M.
Respirology. 2017 Jun 16. doi: 10.1111/resp.13103. [Epub ahead of print]

Structure and dynamics of RNA repeat expansions that cause Huntington's Disease and myotonic dystrophy type 1.
Chen JL, VanEtten DM, Fountain MA, Yildirim I, Disney MD.
Biochemistry. 2017 Jun 15. doi: 10.1021/acs.biochem.7b00252. [Epub ahead of print]

Ethidium Bromide Modifies The Agarose Electrophoretic Mobility of CAG•CTG Alternative DNA Structures Generated by PCR.
Gomes-Pereira M, Monckton DG.
Front Cell Neurosci. 2017 May 30;11:153. doi: 10.3389/fncel.2017.00153. eCollection 2017.

Identification of Exosomal Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relating to Muscle Disease Progress.
Koutsoulidou A, Photiades M, Kyriakides TC, Georgiou K, Prokopi M, Kapnisis K, Lusakowska A, Nearchou M, Christou Y, Papadimas GK, Anayiotos A, Kyriakou K, Kararizou E, Zamba Papanicolaou E, Phylactou LA.
Hum Mol Genet. 2017 Jun 16. doi: 10.1093/hmg/ddx212. [Epub ahead of print]

RNA Localization: Making its Way to the Center Stage.
Chin A, Lécuyer E.
Biochim Biophys Acta. 2017 Jun 16. pii: S0304-4165(17)30197-6. doi: 10.1016/j.bbagen.2017.06.011. [Epub ahead of print]

(CCUG)n RNA toxicity in a Drosophila model for myotonic dystrophy type 2 (DM2) activates apoptosis.
Yenigun VB, Sirito M, Amcheslavky A, Czernuszewicz T, Colonques-Bellmunt J, García-Alcover I, Wojciechowska M, Bolduc C, Chen Z, López Castel A, Krahe R, Bergmann A.
Dis Model Mech. 2017 Jun 16. pii: dmm.026179. doi: 10.1242/dmm.026179. [Epub ahead of print]

Benign and Malignant Tumors in the UK Myotonic Dystrophy Patient Registry.
Alsaggaf R, Wang Y, Marini-Bettolo C, Wood L, Nikolenko N, Lochmüller H, Greene MH, Gadalla SM.
Muscle Nerve. 2017 Jun 29. doi: 10.1002/mus.25736. [Epub ahead of print]

Prospective measurement of quality of life in myotonic dystrophy type 1.
Peric S, Heatwole C, Durovic E, Kacar A, Nikolic A, Basta I, Marjanovic A, Stevic Z, Lavrnic D, Rakocevic Stojanovic V.
Acta Neurol Scand. 2017 Jun 28. doi: 10.1111/ane.12788. [Epub ahead of print]

Downregulation of the Glial GLT1 Glutamate Transporter and Purkinje Cell Dysfunction in a Mouse Model of Myotonic Dystrophy.
Sicot G, Servais L, Dinca DM, Leroy A, Prigogine C, Medja F, Braz SO, Huguet-Lachon A, Chhuon C, Nicole A, Gueriba N, Oliveira R, Dan B, Furling D, Swanson MS, Guerrera IC, Cheron G, Gourdon G, Gomes-Pereira M.
Cell Rep. 2017 Jun 27;19(13):2718-2729. doi: 10.1016/j.celrep.2017.06.006.

Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS.
Gourdon G, Meola G.
Front Cell Neurosci. 2017 Apr 20;11:101. doi: 10.3389/fncel.2017.00101. eCollection 2017.

A Flow Cytometry-Based Screen Identifies MBNL1 Modulators that Rescue Splicing Defects in Myotonic Dystrophy Type I.
Zhang F, Bodycombe NE, Haskell KM, Sun YL, Wang ET, Morris CA, Jones LH, Wood LD, Pletcher MT.
Hum Mol Genet. 2017 May 23. doi: 10.1093/hmg/ddx190. [Epub ahead of print]

A 9-year follow-up study of the natural progression of upper limb performance in myotonic dystrophy type 1: A similar decline for phenotypes but not for gender.
Raymond K, Levasseur M, Mathieu J, Desrosiers J, Gagnon C.
Neuromuscul Disord. 2017 May 2. pii: S0960-8966(16)30807-0. doi: 10.1016/j.nmd.2017.04.007. [Epub ahead of print]

Effects of 1-month withdrawal of ventilatory support in hypercapnic myotonic dystrophy type 1.
O'Donoghue FJ, Borel JC, Dauvilliers Y, Levy P, Tamisier R, Pépin JL.
Respirology. 2017 May 9. doi: 10.1111/resp.13068. [Epub ahead of print]

Hard ways towards adulthood: the transition phase in young people with myotonic dystrophy.
Baldanzi S, Ricci G, Simoncini C, Cosci O Di Coscio M, Siciliano G.
Acta Myol. 2016 Dec;35(3):145-149.

Management of cardiac involvement in muscular dystrophies: paediatric versus adult forms.
Palladino A, D'Ambrosio P, Papa AA, Petillo R, Orsini C, Scutifero M, Nigro G, Politano L.
Acta Myol. 2016 Dec;35(3):128-134.

Deregulation of microRNAs in blood and skeletal muscles of myotonic dystrophy type 1 patients.
Ambrose KK, Ishak T, Lian LH, Goh KJ, Wong KT, Ahmad-Annuar A, Thong MK.
Neurol India. 2017 May-Jun;65(3):512-517. doi: 10.4103/neuroindia.NI_237_16.

Ancient antagonism between CELF and RBFOX families tunes mRNA splicing outcomes.
Gazzara MR, Mallory MJ, Roytenberg R, Lindberg J, Jha A, Lynch KW, Barash Y.
Genome Res. 2017 May 16. pii: gr.220517.117. doi: 10.1101/gr.220517.117. [Epub ahead of print]

Toward a more personalized motor function rehabilitation in Myotonic dystrophy type 1: The role of neuroplasticity.
Portaro S, Naro A, Chillura A, Billeri L, Bramanti A, Bramanti P, Rodolico C, Calabrò RS.
PLoS One. 2017 May 25;12(5):e0178470. doi: 10.1371/journal.pone.0178470.

Cortical Thickness and White Matter Integrity are Associated with CTG Expansion Size in Myotonic Dystrophy Type I.
Yoo WK, Park YG, Choi YC, Kim SM.
Yonsei Med J. 2017 Jul;58(4):807-815. doi: 10.3349/ymj.2017.58.4.807.

Survey of Canadian Myotonic Dystrophy Patients' Access to Computer Technology.
Climans SA, Piechowicz C, Koopman WJ, Venance SL.
Can J Neurol Sci. 2017 May 24:1-5. doi: 10.1017/cjn.2017.47. [Epub ahead of print]

Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.
Meola G, Biasini F, Valaperta R, Costa E, Cardani R.
J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8504-1. [Epub ahead of print]

Subtly modulating Glycogen Synthase Kinase 3 β: allosteric inhibitors development and their potential for the treatment of chronic diseases.
Palomo V, Pérez DI, Roca C, Anderson C, Rodriguez-Muela N, Pérez C, Morales-Garcia JA, Reyes JA, Campillo NE, Pérez-Castillo AM, Rubin LL, Timchenko LT, Gil C, Martínez A.
J Med Chem. 2017 May 26. doi: 10.1021/acs.jmedchem.7b00395. [Epub ahead of print]

Left ventricular longitudinal strain impairment predicts cardiovascular events in asymptomatic type 1 myotonic dystrophy.
Garcia R, Rehman M, Goujeau C, Degand B, Le Gal F, Stordeur B, Labarre Q, Christiaens L, Bouleti C.
Int J Cardiol. 2017 May 19. pii: S0167-5273(17)32086-7. doi: 10.1016/j.ijcard.2017.05.061. [Epub ahead of print]

Classification of Involuntary Movements in Dogs: Myoclonus and Myotonia.
Lowrie M, Garosi L.
J Vet Intern Med. 2017 May 30. doi: 10.1111/jvim.14771. [Epub ahead of print]

Myotonic Dystrophy: Approach to Therapy.
Thornton CA, Wang E, Carrell EM.
Curr Opin Genet Dev. 2017 Apr 1;44:135-140. doi: 10.1016/j.gde.2017.03.007. [Epub ahead of print]

The UK Myotonic Dystrophy Patient Registry: Facilitating and Accelerating Clinical Research.
Wood L, Cordts I, Atalaia A, Marini-Bettolo C, Maddison P, Phillips M, Roberts M, Rogers M, Hammans S, Straub V, Petty R, Orrell R, Monckton DG, Nikolenko N, Jimenez-Moreno AC, Thompson R, Hilton-Jones D, Turner C, Lochmüller H.
J Neurol. 2017 Apr 10. doi: 10.1007/s00415-017-8483-2. [Epub ahead of print]

Reduced Cytoplasmic MBNL1 is an Early Event in a Brain-Specific Mouse Model of Myotonic Dystrophy.
Wang PY, Lin YM, Wang LH, Kuo TY, Cheng SJ, Wang GS.
Hum Mol Genet. 2017 Mar 24. doi: 10.1093/hmg/ddx115.

Delusional and Psychotic Disorders in Juvenile Myotonic Dystrophy Type-1.
Jacobs D, Willekens D, de Die-Smulders C, Frijns JP, Steyaert J.
Am J Med Genet B Neuropsychiatr Genet. 2017 Apr 27. doi: 10.1002/ajmg.b.32524. [Epub ahead of print]

Arrhythmic Risk Evaluation in Myotonic Dystrophy: The Importance of Selection Criteria and Methodological Approach.
Russo V, Papa AA, Rago A, Nigro G.
Clin Auton Res. 2017 Apr 27. doi: 10.1007/s10286-017-0421-y. [Epub ahead of print]

Trinucleotide-Repeat Expanded and Normal DMPK Transcripts Contain Unusually Long Poly(A) Tails Despite Differential Nuclear Residence.
Gudde AEEG, van Kessel IDG, André LM, Wieringa B, Wansink DG.
Biochim Biophys Acta. 2017 Apr 18. pii: S1874-9399(17)30022-6. doi: 10.1016/j.bbagrm.2017.04.002. [Epub ahead of print]

Single-Tube Dodecaplex PCR Panel of Polymorphic Microsatellite Markers Closely Linked to the DMPK CTG Repeat for Preimplantation Genetic Diagnosis of Myotonic Dystrophy Type 1.
Lian M, Zhao M, Lee CG, Chong SS.
Clin Chem. 2017 Apr 20. pii: clinchem.2017.271528. doi: 10.1373/clinchem.2017.271528. [Epub ahead of print]

Optical Mapping Approaches on Muscleblind-Like Compound Knockout Mice for Understanding Mechanistic Insights Into Ventricular Arrhythmias in Myotonic Dystrophy.
Chou CC, Chang PC, Wei YC, Lee KY.
J Am Heart Assoc. 2017 Apr 17;6(4). pii: e005191. doi: 10.1161/JAHA.116.005191.

Structural Characteristics of Simple RNA Repeats Associated with Disease and their Deleterious Protein Interactions.
Ciesiolka A, Jazurek M, Drazkowska K, Krzyzosiak WJ.
Front Cell Neurosci. 2017 Apr 11;11:97. doi: 10.3389/fncel.2017.00097.

2D and 3D FISH of Expanded Repeat Rnas in Human Lymphoblasts.
Urbanek MO, Michalak M, Krzyzosiak WJ.
Methods. 2017 Apr 9. pii: S1046-2023(16)30386-3. doi: 10.1016/j.ymeth.2017.04.002. [Epub ahead of print]

Quality of Life and Excessive Daytime Sleepiness In Children And Adolescents With Myotonic Dystrophy Type 1.
Ho G, Widger J, Cardamone M, Farrar MA.
Sleep Med. 2017 Apr;32:92-96. doi: 10.1016/j.sleep.2016.12.005.

Muscle-specific Expression of the RNA-binding Protein Staufen1 Induces Progressive Skeletal Muscle Atrophy via Regulation of Phosphatase Tensin Homolog.
Crawford Parks TE, Ravel-Chapuis A, Bondy-Chorney E, Renaud JM, Côté J, Jasmin BJ.
Hum Mol Genet. 2017 Mar 24. doi: 10.1093/hmg/ddx085. 

Misregulation of Calcium-Handling Proteins Promotes Hyperactivation of Calcineurin-NFAT Signaling in Skeletal Muscle of DM1 Mice.
Ravel-Chapuis A, Bélanger G, Côté J, Michel RN, Jasmin BJ.
Hum Mol Genet. 2017 Mar 27. doi: 10.1093/hmg/ddx109.

Drosophila melanogaster As a Model Organism to Study RNA Toxicity of Repeat Expansion-Associated Neurodegenerative and Neuromuscular Diseases.
Koon AC, Chan HY.
Front Cell Neurosci. 2017 Mar 21;11:70. doi: 10.3389/fncel.2017.00070.

Analysis of CTG Repeat Length Variation in the DMPK Gene in ihe General Population and the Molecular Diagnosis of Myotonic Dystrophy Type 1 in Malaysia.
Ambrose KK, Ishak T, Lian LH, Goh KJ, Wong KT, Ahmad-Annuar A, Thong MK.
BMJ Open. 2017 Mar 31;7(3):e010711. doi: 10.1136/bmjopen-2015-010711.

New Developments in RAN Translation: Insights from Multiple Diseases.
Cleary JD, Ranum LP.
Curr Opin Genet Dev. 2017 Mar 30;44:125-134. doi: 10.1016/j.gde.2017.03.006. [Epub ahead of print]

Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes.
Yum K, Wang ET, Kalsotra A.
Curr Opin Genet Dev. 2017 Feb 14;44:30-37. doi: 10.1016/j.gde.2017.01.007. [Epub ahead of print]

RNA toxicity and foci formation in microsatellite expansion diseases.
Zhang N, Ashizawa T.
Curr Opin Genet Dev. 2017 Feb 13;44:17-29. doi: 10.1016/j.gde.2017.01.005. [Epub ahead of print]

Learning disabilities in neuromuscular disorders: a springboard for adult life.
Astrea G, Battini R, Lenzi S, Frosini S, Bonetti S, Moretti E, Perazza S, Santorelli FM, Pecini C.
Acta Myol. 2016 Oct;35(2):90-95.

Increased heterogeneity of ventricular repolarization in myotonic dystrophy type 1 population.
Russo V, Papa AA, Rago A, D'Ambrosio P, Cimmino G, Palladino A, Politano L, Nigro G.
Acta Myol. 2016 Oct;35(2):100-106.

Voltage-directed cavo-tricuspid isthmus ablation using a novel ablation catheter mapping technology in a myotonic dystrophy type I patient.
Russo V, Rago A, Papa AA, Di Meo F, Ciardiello C, Cimmino G, Nigro G.
Acta Myol. 2016 Oct;35(2):109-113.

CpG Methylation, a Parent-of-Origin Effect for Maternal-Biased Transmission of Congenital Myotonic Dystrophy.
Barbé L, Lanni S, López-Castel A, Franck S, Spits C, Keymolen K, Seneca S, Tomé S, Miron I, Letourneau J, Liang M, Choufani S, Weksberg R, Wilson MD, Sedlacek Z, Gagnon C, Musova Z, Chitayat D, Shannon P, Mathieu J, Sermon K, Pearson CE.
Am J Hum Genet. 2017 Mar 2;100(3):488-505. doi: 10.1016/j.ajhg.2017.01.033.

Elevated Plasma Levels of Cardiac Troponin-I Predict Left Ventricular Systolic Dysfunction in Patients with Myotonic Dystrophy Type 1: A Multicentre Cohort Follow-up Study.
Hamilton MJ, Robb Y, Cumming S, Gregory H, Duncan A, Rahman M, McKeown A, McWilliam C, Dean J, Wilcox A, Farrugia ME, Cooper A, McGhie J, Adam B, Petty R; Scottish Myotonic Dystrophy Consortium., Longman C, Findlay I, Japp A, Monckton DG, Denvir MA.
PLoS One. 2017 Mar 21;12(3):e0174166. doi: 10.1371/journal.pone.0174166.

Further Evidence for the Reliability and Validity of the Fatigue and Daytime Sleepiness Scale.
Gallais B, Gagnon C, Forgues G, Côté I, Laberge L.
J Neurol Sci. 2017 Apr 15;375:23-26. doi: 10.1016/j.jns.2017.01.032.

Role of Electrophysiological Evaluation for the Best Device Choice to Prevent Sudden Cardiac Death in Patients with Myotonic Dystrophy Type 1 and Emery Dreifuss Muscular Dystrophy.
Russo V, Politano L, Nigro G.
Trends Cardiovasc Med. 2017 Feb 5. pii: S1050-1738(17)30013-0. doi: 10.1016/j.tcm.2017.02.001. [Epub ahead of print]

Cutaneous Neoplasms in Myotonic Dystrophy Type 1.
Marcoval J, Olivé M, Bonfill-Ortí M, Martínez-Molina L, Talavera-Belmonte A.
Dermatology. 2017 Mar 2. doi: 10.1159/000456074. [Epub ahead of print]

Cardiac Autonomic Function in Type 1 and Type 2 Myotonic Dystrophy.
Bienias P, Łusakowska A, Ciurzyński M, Rymarczyk Z, Irzyk K, Konwerski M, Ciąpała K, Kowalski P, Kamińska A, Pruszczyk P.
Clin Auton Res. 2017 Mar 20. doi: 10.1007/s10286-017-0413-y. [Epub ahead of print]

Advances in Assessing Myotonia: Can Sensor-engineered Glove have a Role?
Portaro S, Russo M, Naro A, Bramanti A, Bramanti P, Rodolico C, Calabrò RS.
J Neurol Sci. 2017 Apr 15;375:3-7. doi: 10.1016/j.jns.2017.01.038.

Pigmentation Phenotype, Photosensitivity and Skin Neoplasms in Patients with Myotonic Dystrophy.
Gadalla SM, Hilbert JE, Martens WB, Givens S, Moxley RT 3rd, Greene MH.
Eur J Neurol. 2017 Mar 20. doi: 10.1111/ene.13276. [Epub ahead of print]

Quantitative Assessment of Trunk Muscles Involvement in Patients with Myotonic Dystrophy Type 1 Using a Whole Body Muscle Magnetic Resonance Imaging.
Park D, Park JS.
Eur Neurol. 2017 Mar 14;77(5-6):238-245. doi: 10.1159/000460291. [Epub ahead of print]

CRISPR/Cas9-Induced (CTG⋅CAG)n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing.
van Agtmaal EL, André LM, Willemse M, Cumming SA, van Kessel ID, van den Broek WJ, Gourdon G, Furling D, Mouly V, Monckton DG, Wansink DG, Wieringa B.
Mol Ther. 2017 Jan 4;25(1):24-43. doi: 10.1016/j.ymthe.2016.10.014.

Incidence and Predictors of Sudden Death, Major Conduction Defects and Sustained Ventricular Tachyarrhythmias in 1388 Patients with Myotonic Dystrophy Type 1.
Wahbi K, Babuty D, Probst V, Wissocque L, Labombarda F, Porcher R, Bécane HM, Lazarus A, Béhin A, Laforêt P, Stojkovic T, Clementy N, Dussauge AP, Gourraud JB, Pereon Y, Lacour A, Chapon F, Milliez P, Klug D, Eymard B, Duboc D.
Eur Heart J. 2016 Dec 9. doi: 10.1093/eurheartj/ehw569. [Epub ahead of print]

Immortalized Human Myotonic Dystrophy Muscle Cell Lines to Assess Therapeutic Compounds.
Ludovic A, Micaela PE, Magdalena M, Audrey B, Damily DD, Naïra N, Frédérique R, Arnaud J, Frédérique EV, Kamel M, Mark T, Jack P, Christophe B, Anne B, Jean-Francois D, Vincent M, Arnaud KF, Denis F.
Dis Model Mech. 2017 Feb 10. pii: dmm.027367. doi: 10.1242/dmm.027367. [Epub ahead of print]

Myotonic Dystrophy: Disease Repeat Range, Penetrance, Age of Onset, and Relationship between Repeat Size and Phenotypes.
Yum K, Wang ET, Kalsotra A.
Curr Opin Genet Dev. 2017 Feb 14;44:30-37. doi: 10.1016/j.gde.2017.01.007. [Epub ahead of print]

Myotonic Dystrophy Type 1 Patient-derived iPSCs for the Investigation of CTG Repeat Instability.
Ueki J, Nakamori M, Nakamura M, Nishikawa M, Yoshida Y, Tanaka A, Morizane A, Kamon M, Araki T, Takahashi MP, Watanabe A, Inagaki N, Sakurai H.
Sci Rep. 2017 Feb 13;7:42522. doi: 10.1038/srep42522.

Electromechanical Delays during a Fatiguing Exercise and Recovery in Patients with Myotonic Dystrophy Type 1.
Esposito F, Cè E, Rampichini S, Monti E, Limonta E, Fossati B, Meola G.
Eur J Appl Physiol. 2017 Feb 14. doi: 10.1007/s00421-017-3558-4. [Epub ahead of print]

Apical Left Ventricular Myocardial Dysfunction is an Early Feature of Cardiac Involvement in Myotonic Dystrophy Type 1.
Garcia R, Labarre Q, Degand B, Ingrand P, Le Gal F, Bonnet B, Delaubier A, Guillou C, Gellen B, Coisne D, Bouleti C, Christiaens L.
Echocardiography. 2017 Feb 13. doi: 10.1111/echo.13426. [Epub ahead of print]

Hereditary Myopathies with Early Respiratory Insufficiency in Adults.
Naddaf E, Milone M.
Muscle Nerve. 2017 Feb 9. doi: 10.1002/mus.25602. [Epub ahead of print]

Longitudinal course of lung function in myotonic dystrophy type 1.
Thil C, Agrinier N, Chenuel B, Poussel M.
Muscle Nerve. 2017 Feb 9. doi: 10.1002/mus.25604. [Epub ahead of print]

Functional impairment in patients with myotonic dystrophy type 1 can be assessed by an ataxia rating scale (SARA).
DiPaolo G, Jimenez-Moreno C, Nikolenko N, Atalaia A, Monckton DG, Guglieri M, Lochmüller H.
J Neurol. 2017 Feb 6. doi: 10.1007/s00415-017-8399-x. [Epub ahead of print]

Brain Involvement in Myotonic Dystrophy Type 1: A Morphometric and Diffusion Tensor Imaging Study with Neuropsychological Correlation.
Cabada T, Iridoy M, Jericó I, Lecumberri P, Seijas R, Gargallo A, Gomez M.
Arch Clin Neuropsychol. 2017 Feb 6:1-12. doi: 10.1093/arclin/acx008. [Epub ahead of print]

Association of peripheral neuropathy with sleep-related breathing disorders in myotonic dystrophies.
Banach M, Antczak J, Rola R.
Neuropsychiatr Dis Treat. 2017 Jan 12;13:133-140. doi: 10.2147/NDT.S123908.

Pseudouridine modification inhibits muscleblind-like 1 (MBNL1) binding to CCUG repeats and minimally structured RNA through reduced RNA flexibility.
deLorimier E, Hinman MN, Copperman J, Datta K, Guenza M, Berglund JA.
J Biol Chem. 2017 Jan 27. pii: jbc.M116.770768. doi: 10.1074/jbc.M116.770768. [Epub ahead of print]

The CELF1 RNA-Binding Protein Regulates Decay of Signal Recognition Particle mRNAs and Limits Secretion in Mouse Myoblasts.
Russo J, Lee JE, López CM, Anderson J, Nguyen TP, Heck AM, Wilusz J, Wilusz CJ.
PLoS One. 2017 Jan 27;12(1):e0170680. doi: 10.1371/journal.pone.0170680.

Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat.
Gudde AE, van Heeringen SJ, de Oude AI, van Kessel ID, Estabrook J, Wang ET, Wieringa B, Wansink DG.
RNA Biol. 2017 Jan 19:0. doi: 10.1080/15476286.2017.1279787. [Epub ahead of print]

Prevalence of myotonic dystrophy type 1 in adults in western Sweden.
Lindberg C, Bjerkne F.
Neuromuscul Disord. 2016 Dec 13. pii: S0960-8966(16)30053-0. doi: 10.1016/j.nmd.2016.12.005. [Epub ahead of print]

Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1.
Fritegotto C, Ferrati C, Pegoraro V, Angelini C.
Neurol Sci. 2017 Jan 11. doi: 10.1007/s10072-017-2811-2. [Epub ahead of print]

Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.
Meola G, Cardani R.
Neurol Sci. 2017 Jan 11. doi: 10.1007/s10072-016-2805-5. [Epub ahead of print] Review.

Cutaneous features of myotonic dystrophy types 1 and 2: Implication of premature aging and vitamin D homeostasis.
Campione E, Botta A, Di Prete M, Rastelli E, Gibellini M, Petrucci A, Bernardini S, Novelli G, Bianchi L, Orlandi A, Massa R, Terracciano C.
Neuromuscul Disord. 2016 Nov 16. pii: S0960-8966(16)30856-2. doi: 10.1016/j.nmd.2016.11.004. [Epub ahead of print]

Is one trial enough for repeated testing? Same-day assessments of walking, mobility and fine hand use in people with myotonic dystrophy type 1.
Kierkegaard M, Petitclerc E, Hébert LJ, Gagnon C.
Neuromuscul Disord. 2016 Dec 5. pii: S0960-8966(16)30790-8. doi: 10.1016/j.nmd.2016.11.018. [Epub ahead of print]

Short intron-derived ncRNAs.
Hubé F, Ulveling D, Sureau A, Forveille S, Francastel C.
Nucleic Acids Res. 2017 Jan 3. pii: gkw1341. doi: 10.1093/nar/gkw1341. [Epub ahead of print]

Steinert syndrome and repercussions in dental medicine.
Baptista H, Lopes Cardoso I.
Arch Oral Biol. 2016 Dec 23;75:37-47. doi: 10.1016/j.archoralbio.2016.12.008. [Epub ahead of print] Review.

Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1.
Perfetti A, Greco S, Cardani R, Fossati B, Cuomo G, Valaperta R, Ambrogi F, Cortese A, Botta A, Mignarri A, Santoro M, Gaetano C, Costa E, Dotti MT, Silvestri G, Massa R, Meola G, Martelli F.
Sci Rep. 2016 Dec 1;6:38174. doi: 10.1038/srep38174.

Cardiac Abnormalities in Congenital and Childhood Myotonic Muscular Dystrophy Type 1.
Sharma A, Singh S, Mishra SK.
Neuropediatrics. 2016 Dec 19. [Epub ahead of print]

Myotonic dystrophy type 1: role of CCG, CTC and CGG interruptions within DMPK alleles in the pathogenesis and molecular diagnosis.
Santoro M, Masciullo M, Silvestri G, Novelli G, Botta A.
Clin Genet. 2016 Dec 19. doi: 10.1111/cge.12954. [Epub ahead of print] Review.

Precise small-molecule recognition of a toxic CUG RNA repeat expansion.
Rzuczek SG, Colgan LA, Nakai Y, Cameron MD, Furling D, Yasuda R, Disney MD.
Nat Chem Biol. 2016 Dec 12. doi: 10.1038/nchembio.2251. [Epub ahead of print]

Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1.
Wahbi K, Babuty D, Probst V, Wissocque L, Labombarda F, Porcher R, Bécane HM, Lazarus A, Béhin A, Laforêt P, Stojkovic T, Clementy N, Dussauge AP, Gourraud JB, Pereon Y, Lacour A, Chapon F, Milliez P, Klug D, Eymard B, Duboc D.
Eur Heart J. 2016 Dec 9. pii: ehw569. [Epub ahead of print]

Preferential changes of skeletal muscle echogenicity in myotonic dystrophy type 1.
Takamatsu N, Sogawa K, Nodera H, Hashiguchi S, Osaki Y, Saito M, Mori A, Izumi Y, Kaji R.
Eur J Neurol. 2016 Dec 9. doi: 10.1111/ene.13212. [Epub ahead of print]

A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland.
Lefter S, Hardiman O, Ryan AM.

Neurology. 2016 Dec 7. pii: 10.1212/WNL.0000000000003504. [Epub ahead of print]

Sleepiness and Sleep-related Breathing Disorders in Myotonic Dystrophy and Responses to Treatment: A Prospective Cohort Study.
West SD, Lochmüller H, Hughes J, Atalaia A, Marini-Bettolo C, Baudouin SV, Anderson KN.
J Neuromuscul Dis. 2016 Nov 29;3(4):529-537.

Autoregulation of MBNL1 function by exon 1 exclusion from MBNL1 transcript.
Konieczny P, Stepniak-Konieczna E, Taylor K, Sznajder ŁJ, Sobczak K.
Nucleic Acids Res. 2016 Nov 29. pii: gkw1158. [Epub ahead of print]

Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2.
Peric S, Rakocevic Stojanovic V, Mandic Stojmenovic G, Ilic V, Kovacevic M, Parojcic A, Pesovic J, Mijajlovic M, Savic-Pavicevic D, Meola G.
Neurol Sci. 2016 Nov 28. [Epub ahead of print]

Unusual structures of CCTG repeats and their participation in repeat expansion.
Guo P, Lam SL.
Biomol Concepts. 2016 Dec 1;7(5-6):331-340. doi: 10.1515/bmc-2016-0024.

Identification and characterization of 5' CCG interruptions in complex DMPK expanded alleles.
Botta A, Rossi G, Marcaurelio M, Fontana L, D'Apice MR, Brancati F, Massa R, G Monckton D, Sangiuolo F, Novelli G.
Eur J Hum Genet. 2016 Nov 23. doi: 10.1038/ejhg.2016.148. [Epub ahead of print]

A review of muscle, and performance-based assessment instruments in DM1
Symonds T, Campbell P, Randall JA.
Muscle Nerve. 2016 Nov 11. doi: 10.1002/mus.25468.

Physical Function and Mobility in Children with Congenital Myotonic Dystrophy
Pucillo EM, DiBella DL, Hung M, Bounsanga J, Crockett B, Dixon M, Butterfield RJ, Campbell C, Johnson NE.
Muscle Nerve. 2016 Nov 18. doi: 10.1002/mus.25482.

Left Ventricular Dysfunction and Conduction Disturbances in Patients With Myotonic Muscular Dystrophy Type I and II
Tanawuttiwat T, Wagner KR, Tomaselli G, Nazarian S.
JAMA Cardiol. 2016 Nov 9. doi: 10.1001/jamacardio.2016.4145.

A Review of Patient Reported Outcome Measures for Use in DM1 Patients
Symonds T, Randall JA, Campbell P.
Muscle Nerve. 2016 Nov 11. doi: 10.1002/mus.25469.

Cognitive decline over time in adults with myotonic dystrophy type 1: A 9-year longitudinal study.
Gallais B, Gagnon C, Mathieu J, Richer L.
Neuromuscul Disord. 2016 Oct 14. pii: S0960-8966(16)30846-X. doi: 10.1016/j.nmd.2016.10.003. [Epub ahead of print]

Dysregulation of mRNA Localization and Translation in Genetic Disease.
Wang ET, Taliaferro JM, Lee JA, Sudhakaran IP, Rossoll W, Gross C, Moss KR, Bassell GJ.
J Neurosci. 2016 Nov 9;36(45):11418-11426.

The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study
Johnson NE, Hung M, Nasser E, Hagerman KA, Chen W, Ciafaloni E, Heatwole CR.
J Neuromuscul Dis. 2015 Oct 7;2(4):447-452.

Can Long-term Thiamine Treatment Improve the Clinical Outcomes of Myotonic Dystrophy Type 1?
Costantini A, Trevi E, Pala MI, Fancellu R.
Neural Regen Res. 2016 Sep;11(9):1487-1491.

Developmental Milestones and Quality of Life Assessment in a Congenital Myotonic Dystrophy Cohort
Prasad M, Hicks R, MacKay M, Nguyen CT, Campbell C.
J Neuromuscul Dis. 2016 Aug 30;3(3):405-412.

Do Psychosocial Interventions Improve Quality of Life and Wellbeing in Adults with Neuromuscular Disorders? A Systematic Review and Narrative Synthesis
Walklet E, Muse K, Meyrick J, Moss T.
J Neuromuscul Dis. 2016 Aug 30;3(3):347-362.

Can Human Pluripotent Stem Cell-Derived Cardiomyocytes Advance Understanding of Muscular Dystrophies?
Kalra S, Montanaro F, Denning C.
J Neuromuscul Dis. 2016 Aug 30;3(3):309-332.

Development of Pharmacophore Models for Small Molecules Targeting RNA: Application to the RNA Repeat Expansion in Myotonic Dystrophy Type 1.
Angelbello AJ, González ÀL, Rzuczek SG, Disney MD.
Bioorg Med Chem Lett. 2016 Oct 13. pii: S0960-894X(16)31065-4. doi: 10.1016/j.bmcl.2016.10.037.

MRI Findings and Cognitive Functions in a Small Cohort of Myotonic Dystrophy Type 1: Retrospective Analyses
Bajrami A, Azman F, Yayla V, Cagirici S, Keskinkiliç C, Sozer N.
Neuroradiol J. 2016 Nov 11. pii: 1971400916678223.

Myotonic Dystrophy Type 1 Management and Therapeutics
Smith CA, Gutmann L.
Curr Treat Options Neurol. 2016 Dec;18(12):52.

High-sensitive cardiac troponin T (hs-cTnT) assay as serum biomarker to predict cardiac risk in myotonic dystrophy: A case-control study.
Valaperta R, Gaeta M, Cardani R, Lombardi F, Rampoldi B, De Siena C, Mori F, Fossati B, Gaia P, Ferraro OE, Villani S, Iachettini S, Piccoli M, Cirillo F, Pusineri E, Meola G, Costa E.
Clin Chim Acta. 2016 Oct 22;463:122-128. doi: 10.1016/j.cca.2016.10.026.

Defining the performance parameters of a rapid screening tool for myotonic dystrophy type 1 based on triplet-primed PCR and melt curve analysis.
Lian M, Law HY, Lee CG, Chong SS.
Expert Rev Mol Diagn. 2016 Nov;16(11):1221-1232.

Effects of Functional Electrical Stimulation Lower Extremity Training in Myotonic Dystrophy Type I: A Pilot Controlled Study.
Cudia P, Weis L, Baba A, Kiper P, Marcante A, Rossi S, Angelini C, Piccione F.
Am J Phys Med Rehabil. 2016 Nov;95(11):809-817.

Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts.
Tajhya RB, Hu X, Tanner MR, Huq R, Kongchan N, Neilson JR, Rodney GG, Horrigan FT, Timchenko LT, Beeton C.
Cell Death Dis. 2016 Oct 20;7(10):e2426. doi: 10.1038/cddis.2016.324.

Major involvement of trunk muscles in myotonic dystrophy type 1.
Solbakken G, Ørstavik K, Hagen T, Dietrichs E, Naerland T.
Acta Neurol Scand. 2016 Dec;134(6):467-473. doi: 10.1111/ane.12565.

Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.
Fitzgerald BP, Conn KM, Smith J, Walker A, Parkhill AL, Hilbert JE, Luebbe EA, Moxley Iii RT.
J Neurol. 2016 Oct 12.

Molecular Diagnosis of Myotonic Dystrophy.
Chakraborty S, Vatta M, Bachinski LL, Krahe R, Dlouhy S, Bai S.
Curr Protoc Hum Genet. 2016 Oct 11;91:9.29.1-9.29.19. doi: 10.1002/cphg.22.

Five-year study of quality of life in myotonic dystrophy.
Peric S, Vujnic M, Dobricic V, Marjanovic A, Basta I, Novakovic I, Lavrnic D, Rakocevic-Stojanovic V.
Acta Neurol Scand. 2016 Nov;134(5):346-351.

A Ligand That Targets CUG Trinucleotide Repeats.
Li J, Matsumoto J, Bai LP, Murata A, Dohno C, Nakatani K.
Chemistry. 2016 Oct 10;22(42):14881-14889. 

Factors influencing compliance with non-invasive ventilation at long-term in patients with myotonic dystrophy type 1: A prospective cohort.
Boussaïd G, Lofaso F, Santos DB, Vaugier I, Pottier S, Prigent H, Orlikowski D, Bahrami S.
Neuromuscul Disord. 2016 Oct;26(10):666-674.

Conservation of context-dependent splicing activity in distant Muscleblind homologs.
Oddo JC, Saxena T, McConnell OL, Berglund JA, Wang ET.
Nucleic Acids Res. 2016 Sep 30;44(17):8352-62. 

Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy.
Wagner SD, Struck AJ, Gupta R, Farnsworth DR, Mahady AE, Eichinger K, Thornton CA, Wang ET, Berglund JA.
PLoS Genet. 2016 Sep 28;12(9):e1006316. 

Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification.
De Antonio M, Dogan C, Hamroun D, Mati M, Zerrouki S, Eymard B, Katsahian S, Bassez G; French Myotonic Dystrophy Clinical Network.
Rev Neurol (Paris). 2016 Sep 21. pii: S0035-3787(16)30205-3. 

Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
Long C, Amoasii L, Bassel-Duby R, Olson EN.
JAMA Neurol. 2016 Sep 26.

Expanded DMPK repeats in dizygotic twins referred for diagnosis of autism versus absence of expanded DMPK repeats at screening of 330 children with autism.
Musova Z, Hancarova M, Havlovicova M, Pourova R, Hrdlicka M, Kraus J, Trkova M, Stejskal D, Sedlacek Z.
Neuropsychiatr Dis Treat. 2016 Sep 19;12:2367-2372.

The motor function measure (MFM) in the myotonic dystrophy type 1 population: Description and responsiveness.
de Lattre C, Rippert P, Bassez G, Hamroun D, Poirot I, Vuillerot C.
Ann Phys Rehabil Med. 2016 Sep;59S:e81.

Participation restriction in childhood phenotype of myotonic dystrophy type 1: a systematic retrospective chart review.
Gagnon C, Kierkegaard M, Blackburn C, Chrestian N, Lavoie M, Bouchard MF, Mathieu J.
Dev Med Child Neurol. 2016 Sep 27. 

Myotonic Dystrophy and Huntington's Disease Care: "We Like to Think We're Making a Difference".
LaDonna KA, Watling CJ, Ray SL, Piechowicz C, Venance SL.
Can J Neurol Sci. 2016 Sep;43(5):678-86.

Defining the performance parameters of a rapid screening tool for myotonic dystrophy type 1 based on triplet-primed PCR and melt curve analysis.
Lian M, Law HY, Lee CG, Chong SS.
Expert Rev Mol Diagn. 2016 Sep 24. 

Disease Phenotypes in a Mouse Model of RNA Toxicity Are Independent of Protein Kinase Cα and Protein Kinase Cβ.
Kim YK, Yadava RS, Mandal M, Mahadevan K, Yu Q, Leitges M, Mahadevan MS.
PLoS One. 2016 Sep 22;11(9):e0163325. 

Neuromuscular transmission abnormalities in myotonic dystrophy type 1: A neurophysiological study.
Bombelli F, Lispi L, Porrini SC, Giacanelli M, Terracciano C, Massa R, Petrucci A.
Clin Neurol Neurosurg. 2016 Aug 29;150:84-88. 

Staufen1s role as a splicing factor and a disease modifier in Myotonic Dystrophy Type I.
Bondy-Chorney E, Crawford Parks TE, Ravel-Chapuis A, Jasmin BJ, Côté J.
Rare Dis. 2016 Aug 19;4(1):e1225644.

Liang R, Dong W, Shen X, Peng X, Aceves AG, Liu Y. J Vis Exp. 2016 Jul 29.
 
Lovadi E, Csereklyei M, Merkli H, Fülöp K, Sebők Á, Karcagi V, Komoly S, Pál E. Muscle Nerve. 2016 Aug 4. 
Choi J, Dixon DM, Dansithong W, Abdallah WF, Roos KP, Jordan MC, Trac B, Lee HS, Comai L, Reddy S. Sci Rep. 2016 Aug 3.
 
Hayashi K, Hamano T, Kawamura Y, Kimura H, Matsunaga A, Ikawa M, Yamamura O, Mutoh T, Higuchi I, Kuriyama M, Nakamoto Y. Eur Neurol. 2016 Jul 29.
 
Sommerville RB, Vincenti MG, Winborn K, Casey A, Stitziel NO, Connolly AM, Mann DL. Trends Cardiovasc Med. 2016 Jun 14.
 
Baldanzi S, Cecchi P, Fabbri S, Pesaresi I, Simoncini C, Angelini C, Bonuccelli U, Cosottini M, Siciliano G. Neuroimage Clin. 2016 Jun 15.
 
Bienias P, Łusakowska A, Ciurzyński M, Rymarczyk Z, Irzyk K, Kurnicka K, Kamińska A, Pruszczyk P. Pacing Clin Electrophysiol. 2016 Jul 22.
 
Renard D, Collombier L, Castelli C, Pouget JP, Kotzki PO, Boudousq V. BMC Neurol. 2016 Jul 13.
 
Leonardis L. Acta Neurol Scand. 2016 Jul 12.
 
 

[Congenital neuromuscular diseases with neonatal respiratory failure excluding myotonic dystrophy type 1 and infantile spinal muscular atrophy. Diagnosis strategy according to a 19-child series].
Raignoux J, Walther-Louvier U, Espil C, Berthomieu L, Uro-Coste E, Rivier F, Cances C. Arch Pediatr. 2016 Jun 30.

Targeting the Heart for Risk Assessment in Myotonic Dystrophy: An Application for Cardiac Magnetic Resonance.
Shah RV, Semigran MJ. Circ Cardiovasc Imaging. 2016 Jul 9.

Cardiac Involvement in Myotonic Dystrophy Type 2 Patients With Preserved Ejection Fraction: Detection by Cardiovascular Magnetic Resonance.
Schmacht L, Traber J, Grieben U, Utz W, Dieringer MA, Kellman P, Blaszczyk E, von Knobelsdorff-Brenkenhoff F, Spuler S, Schulz-Menger J. Circ Cardiovasc Imaging. 2016 Jul 9.

Bilateral Adduction Palsy in a Patient with Myotonic Dystrophy Type 1.
Kim HJ, Oh JH, Kang SY. Exp Neurobiol. 2016 Jun 25.

Integrating Display and Delivery Functionality with a Cell Penetrating Peptide Mimic as a Scaffold for Intracellular Multivalent Multi-targeting.
Bai Y, Nguyen LT, Song Z, Peng S, Lee J, Zheng N, Kapoor I, Hagler LD, Cai K, Cheng J, Chan HY, Zimmerman SC. J Am Chem Soc. 2016 Jun 29.

Focal seizures in a patient with myotonic disorder type 2 co-segregating with a chloride voltage-gated channel 1 gene mutation: a case report.
Peddareddygari LR, Grewal AS, Grewal RP. J Med Case Rep. 2016 Jun 7.

Modeling simple repeat expansion diseases with iPSC technology.
Jaworska E, Kozlowska E, Switonski PM, Krzyzosiak WJ. Cell Mol Life Sci. 2016 Jun 3

Understanding the molecular consequences of inherited muscular dystrophies: advancements through proteomic experimentation.
Fuller HR, Graham LC, Llavero Hurtado M, Wishart TM. Expert Rev Proteomics. 2016 Jul 5

Cognition in myotonic dystrophy type 1: a 5-year follow-up study.
Winblad S, Samuelsson L, Lindberg C, Meola G. Eur J Neurol. 2016 Jun 20.

Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
Herrendorff R, Faleschini MT, Stiefvater A, Erne B, Wiktorowicz T, Kern F, Hamburger M, Potterat O, Kinter J, Sinnreich M. J Biol Chem. 2016 Jun 13.

Disease burden and functional outcomes in congenital myotonic dystrophy: A cross-sectional study.
Johnson NE, Butterfield R, Berggren K, Hung M, Chen W, DiBella D, Dixon M, Hayes H, Pucillo E, Bounsanga J, Heatwole C, Campbell C. Neurology. 2016 Jun 15.

An Overview of Cardiac Management in Neuromuscular Disease.
Hickey RM, Cullen JD, Sachs GM. Open Cardiovasc Med J. 2016 May 27.

Identification of MyoD Interactome Using Tandem Affinity Purification Coupled to Mass Spectrometry.
Boyarchuk E, Robin P, Fritsch L, Joliot V, Ait-Si-Ali S. J Vis Exp. 2016 May 17.

A Molecular Signature of Myalgia in Myotonic Dystrophy 2.
Moshourab R, Palada V, Grunwald S, Grieben U, Lewin GR, Spuler S. EBioMedicine. 2016 May 7.

Relationship of white and gray matter abnormalities to clinical and genetic features in myotonic dystrophy type 1.
Zanigni S, Evangelisti S, Giannoccaro MP, Oppi F, Poda R, Giorgio A, Testa C, Manners DN, Avoni P, Gramegna LL, De Stefano N, Lodi R, Tonon C, Liguori R. Neuroimage Clin. 2016 May 3

A tell tale handshake.
Wander P, Iluyomade A, Sanmartin P, Gupta A, O'Sullivan M. Respir Med Case Rep. 2016 May 3.

Derivation of DM2 affected human embryonic stem cell line Genea066.
Dumevska B, Schaft J, McKernan R, Goel D, Schmidt U. Stem Cell Res. 2016 Mar 16.

Brain Connectomics' Modification to Clarify Motor and Nonmotor Features of Myotonic Dystrophy Type 1.
Serra L, Mancini M, Silvestri G, Petrucci A, Masciullo M, Spanò B, Torso M, Mastropasqua C, Giacanelli M, Caltagirone C, Cercignani M, Meola G, Bozzali M. Neural Plast. 2016

Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.
Yue Y, Binalsheikh IM, Leach SB, Domeier TL, Duan D. Epub 2015 Dec 17.

Quality of life in patients with myotonic dystrophy type 2.
Rakocevic Stojanovic V, Peric S, Paunic T, Pesovic J, Vujnic M, Peric M, Nikolic A, Lavrnic D, Savic Pavicevic D. J Neurol Sci. 2016 Jun 15.
 
Modeling simple repeat expansion diseases with iPSC technology.
Jaworska E, Kozlowska E, Switonski PM, Krzyzosiak WJ. Cell Mol Life Sci. 2016 Jun 3. 
 
 
Raymond K, Levasseur M, Chouinard MC, Mathieu J, Gagnon C. Can J Occup Ther. 2016 Jun 3.
 
Luu LM, Nguyen L, Peng S, Lee J, Lee HY, Wong CH, Hergenrother PJ, Chan HY, Zimmerman SC. ChemMedChem. 2016 Jun 1. 
 
What's in the Literature?
Silvestri NJ, Wolfe GI, Bromberg M, Lacomis D. J Clin Neuromuscul Dis. 2016 Jun 17.
 
Identification of variants in MBNL1 in patients with a myotonic dystrophy-like phenotype.
Larsen M, Kress W, Schoser B, Hehr U, Müller CR, Rost S. Eur J Hum Genet. 2016 May 25. 
 
Drug resistant focal epilepsy in a patient with myotonic dystrophy type 2: casual or causal association?
Giuliano L, Sofia V, Cardani R, Meola G, Zappia M. Neurol Sci. 2016 May 25. 
 
Prevalence of neoplasms in definite and probable mitochondrial disorders.
Finsterer J, Frank M. Mitochondrion. 2016 May 13.
 
Genome therapy of myotonic dystrophy type 1 iPS cells for development of autologous stem cell therapy.
Gao Y, Guo X, Santostefano K, Wang Y, Reid T, Zeng D, Terada N, Ashizawa T, Xia G. Mol Ther. 2016 May 12. 
 
Relationship between muscle impairments, postural stability, and gait parameters assessed with lower-trunk accelerometry in myotonic dystrophy type 1.
Bachasson D, Moraux A, Ollivier G, Decostre V, Ledoux I, Gidaro T, Servais L, Behin A, Stojkovic T, Hébert LJ, Puymirat J, Eymard B, Bassez G, Hogrel JY. Neuromuscul Disord. 2016 May 12.
 
Pigmented Silk Nanofibrous Composite for Skeletal Muscle Tissue Engineering.
Manchineella S, Thrivikraman G, Khanum KK, Ramamurthy PC, Basu B, Govindaraju T. Adv Healthc Mater. 2016 May 5.
 
"I Know that You Know that I Know": Neural Substrates Associated with Social Cognition Deficits in DM1 Patients.
Serra L, Cercignani M, Bruschini M, Cipolotti L, Mancini M, Silvestri G, Petrucci A, Bucci E, Antonini G, Licchelli L, Spanò B, Giacanelli M, Caltagirone C, Meola G, Bozzali M. PLoS One. 2016 Jun 3.
 
Multidimensional aspects of pain in myotonic dystrophies.
Peric M, Peric S, Rapajic N, Dobricic V, Savic-Pavicevic D, Nesic I, Radojicic S, Novakovic I, Lavrnic D, Rakocevic-Stojanovic V. Acta Myol. 2015 Dec 2.
 
Choudhary P, Nandakumar R, Greig H, Broadhurst P, Dean J, Puranik R, Celermajer DS, Hillis GS. Heart. 2016 May 10. [Epub ahead of print]
 
Costales MG, Rzuczek SG, Disney MD. Bioorg Med Chem Lett. 2016 Jun 1.
 
Xu Y, Halievski K, Henley C, Atchison WD, Katsuno M, Adachi H, Sobue G, Breedlove SM, Jordan CL. J Neurosci. 2016 May 4.
 
Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy.
Chen G, Masuda A, Konishi H, Ohkawara B, Ito M, Kinoshita M, Kiyama H, Matsuura T, Ohno K. Sci Rep. 2016 Apr 29.
Characterization of sarcoplasmic reticulum Ca(2+) ATPase pumps in muscle of patients with myotonic dystrophy and with hypothyroid myopathy. 
Guglielmi V, Oosterhof A, Voermans NC, Cardani R, Molenaar JP, van Kuppevelt TH, Meola G, van Engelen BG, Tomelleri G, Vattemi G. Neuromuscul Disord. 2016 Apr 6.
 
No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected fibromyalgia syndrome.
van Vliet J, Verrips A, Tieleman AA, Scheffer H, Cats HA, den Broeder AA, van Engelen BG. Neuromuscul Disord. 2016 Apr 6.
 
Myotonic disorders: A review article.
Hahn C, Salajegheh MK. Iran J Neurol. 2016 Jan 5. Review.
 
Ethical and Genetic Aspects Regarding Presymptomatic Testing for Neurodegenerative Diseases. 
Cozaru GC, Aşchie M, Mitroi AF, Poinăreanu I, Gorduza EV. Rev Med Chir Soc Med Nat Iasi. 2016 Jan-Mar.
 
 
Educational and Professional Qualifications of Adults With Myotonic Dystrophies - A Misleading Perception by the Myopathic Face?
Stahl K, Wenninger S, Schüller A, Montagnese F, Schoser B. Fortschr Neurol Psychiatr. 2016 Apr.
 
Effects of Functional Electrical Stimulation Lower Extremity Training in Myotonic Dystrophy Type I: A Pilot Controlled Study. 
Cudia P, Weis L, Baba A, Kiper P, Marcante A, Rossi S, Angelini C, Piccione F. Am J Phys Med Rehabil. 2016 Apr 15.
 
A Population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy. 
Abbott D, Johnson NE, Cannon-Albright LA. Muscle Nerve. 2016 Apr 11.
 
Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy.
Freyermuth F, Rau F, Kokunai Y, Linke T, Sellier C, Nakamori M, Kino Y, Arandel L, Jollet A, Thibault C, Philipps M, Vicaire S, Jost B, Udd B, Day JW, Duboc D, Wahbi K, Matsumura T, Fujimura H, Mochizuki H, Deryckere F, Kimura T, Nukina N, Ishiura S, Lacroix V, Campan-Fournier A, Navratil V, Chautard E, Auboeuf D, Horie M, Imoto K, Lee KY, Swanson MS, Lopez de Munain A, Inada S, Itoh H, Nakazawa K, Ashihara T, Wang E, Zimmer T, Furling D, Takahashi MP, Charlet-Berguerand N. Nat Commun. 2016 Apr 11.
 
Myotonic dystrophy type 1: frequency of ophthalmologic findings.
Ikeda KS, Iwabe-Marchese C, França MC Jr, Nucci A, Carvalho KM. Arq Neuropsiquiatr. 2016 Mar.
 
Baldanzi S, Bevilacqua F, Lorio R, Volpi L, Simoncini C, Petrucci A, Cosottini M, Massimetti G, Tognoni G, Ricci G, Angelini C, Siciliano G. Orphanet J Rare Dis. 2016 Apr 4.
 
Variable genetic penetrance of myotonic dystrophy following the diagnosis of idiopathic polyhydramnios.
Güler B, Kılıç SH, Kızıltan MY. Int J Gynaecol Obstet. 2016 Mar 9.
 
Staufen1 Impairs Stress Granule Formation in Skeletal Muscle Cells from Myotonic Dystrophy type 1 Patients.
Ravel-Chapuis A, Gunnewiek AK, Bélanger G, Parks TE, Côté J, Jasmin BJ. Mol Biol Cell. 2016 Mar 30. 
 
Overweight Is an Independent Risk Factor for Reduced Lung Volumes in Myotonic Dystrophy Type 1.
Seijger CG, Drost G, Posma JM, van Engelen BG, Heijdra YF. PLoS One. 2016 Mar 25.
 
On the Applicability of Elastic Network Models for the Study of RNA CUG Trinucleotide Repeat Overexpansion.
González ÀL, Teixidó J, Borrell JI, Estrada-Tejedor R. PLoS One. 2016 Mar 24
 
Knowledge of Sub-Types Important to Understanding of the Prevalence of Myotonic Dystrophy. 
Theadom A, Rodrigues M, Roxburgh R. Neuroepidemiology. Epub 2016 Mar 15.
 
Myotonic dystrophy type 1 presenting with asymmetric winged scapula. 
Alsharabati M, Erol F, Bayoumi M, Oh SJ. Muscle Nerve. 2016 Mar 11. 
 
A trigger-happy soldier with bilateral ptosis and dysphagia.
Ahmad FM, Hari Kumar KV. Biomed J. 2016 Mar 10. 
 
Restricting calcium currents is required for correct fiber type specification in skeletal muscle. 
Sultana N, Dienes B, Benedetti A, Tuluc P, Szentesi P, Sztretye M, Rainer J,Hess MW, Schwarzer C, Obermair GJ, Csernoch L, Flucher BE. Development. 2016 Mar 10. 
 
Diagnostic support for selected neuromuscular diseases using answer-pattern recognition and data mining techniques: a proof of concept multicenter prospective trial.
Grigull L, Lechner W, Petri S, Kollewe K, Dengler R, Mehmecke S, Schumacher U, Lücke T, Schneider-Gold C, Köhler C, Güttsches AK, Kortum X, Klawonn F. BMC Med Inform Decis Mak. 2016 Mar 8.
 
 
Sleep in Neuromuscular Diseases. 
Fermin AM, Afzal U, Culebras A. Sleep Med Clin. 2016 Mar. Epub 2016 Jan 9.
 
 
 
 
 
Six Serum miRNAs Fail to Validate as Myotonic Dystrophy Type 1 Biomarkers.
Fernandez-Costa JM, Llamusi B, Bargiela A, Zulaica M, Alvarez-Abril MC, Perez-Alonso M, Lopez de Munain A, Lopez-Castel A, Artero R. PLoS One. 2016 Feb 26. 
 
TWEAK Regulates Muscle Functions in a Mouse Model of RNA Toxicity.
Yadava RS, Foff EP, Yu Q, Gladman JT, Zheng TS, Mahadevan MS. PLoS One. 2016 Feb 22.
 
Myotonic Dystrophy Type 1 with Syringomyelia in a Young Patient.
Yu XL, Jia RZ, Shan PY, Yan CZ, Liu AF. Chin Med J (Engl). 2016 Feb 20.
 
Reliable and versatile immortal muscle cell models from healthy and myotonic dystrophy type 1 primary human myoblasts.
Pantic B, Borgia D, Giunco S, Malena A, Kiyono T, Salvatori S, De Rossi A, Giardina E, Sangiuolo F, Pegoraro E, Vergani L, Botta A. Exp Cell Res. 2016 Feb 19. 
 
An Age-Standardized Prevalence Estimate and a Sex and Age Distribution of Myotonic Dystrophy Types 1 and 2 in the Rome Province, Italy.
Vanacore N, Rastelli E, Antonini G, Bianchi ML, Botta A, Bucci E, Casali C, Costanzi-Porrini S, Giacanelli M, Gibellini M, Modoni A, Novelli G, Pennisi EM, Petrucci A, Piantadosi C, Silvestri G, Terracciano C, Massa R. Neuroepidemiology. 2016 Feb 17.
 
A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.
Gudde AE, González-Barriga A, van den Broek WJ, Wieringa B, Wansink DG. Hum Mol Genet. 2016 Feb 16.
 
Muscleblind-like 1 suppresses breast cancer metastatic colonization and stabilizes metastasis suppressor transcripts.
Fish L, Pencheva N, Goodarzi H, Tran H, Yoshida M, Tavazoie SF. Genes Dev. 2016 Feb 15.
 
 
Jones K, Pitceathly RD, Rose MR, McGowan S, Hill M, Badrising UA, Hughes T. Cochrane Database Syst Rev. 2016 Feb 9. [Epub ahead of print] Review.
 
Dogan C, De Antonio M, Hamroun D, Varet H, Fabbro M, Rougier F, Amarof K, Arne Bes MC, Bedat-Millet AL, Behin A, Bellance R, Bouhour F, Boutte C, Boyer F, Campana-Salort E, Chapon F, Cintas P, Desnuelle C, Deschamps R, Drouin-Garraud V, Ferrer X, Gervais-Bernard H, Ghorab K, Laforet P, Magot A, Magy L, Menard D, Minot MC, Nadaj-Pakleza A, Pellieux S, Pereon Y, Preudhomme M, Pouget J, Sacconi S, Sole G, Stojkovich T, Tiffreau V, Urtizberea A, Vial C, Zagnoli F, Caranhac G, Bourlier C, Riviere G, Geille A, Gherardi RK, Eymard B, Puymirat J, Katsahian S, Bassez G. PLoS One. 2016 Feb 5.
 
Major involvement of trunk muscles in myotonic dystrophy type 1.
Solbakken G, Ørstavik K, Hagen T, Dietrichs E, Naerland T. Acta Neurol Scand. 2016 Feb 1.
 
Impairment of Odor Recognition in Myotonic Dystrophy Type 1.
Masaoka Y. Brain Nerve. 2016 Feb. Japanese.
 
Social Cognitive Impairment in Myotonic Dystrophy Type 1.
Kobayakawa M. Brain Nerve. 2016 Feb. Japanese. 
 
Clinical Importance of Central Nervous System Dysfunction in Myopathy.
Matsumura T. Brain Nerve. 2016 Feb. Japanese.
 
Comparison of temporal and stride characteristics in myotonic dystrophies type 1 and 2 during dual-task walking. 
Radovanović S, Perić S, Savić-Pavićević D, Dobričić V, Pešović J, Kostić V, Rakočević-Stojanović V. Gait Posture. 2016 Feb. Epub 2015 Dec 20.
 
 
Zhang BW, Cai HF, Wei XF, Sun JJ, Lan XY, Lei CZ, Lin FP, Qi XL, Plath M, Chen H. Int J Mol Sci. 2016 Jan 29.
Bondy-Chorney E, Crawford Parks TE, Ravel-Chapuis A, Klinck R, Rocheleau L, Pelchat M, Chabot B, Jasmin BJ, Côté J. PLoS Genet. 2016 Jan 29.
 
Nikolić-Kokić A, Marinković D, Perić S, Stević Z, Spasić MB, Blagojević D, Rakočević-Stojanović V. Redox Rep. 2016 Jan 28.
 
Choi SH, Yang HK, Hwang JM, Park KS. Graefes Arch Clin Exp Ophthalmol. 2016 Jan 27.
 
 
Russo V, Rago A, Nigro G. Int J Cardiol. 2016 Jan 13.
 
In vivo assessment of muscle membrane properties in myotonic dystrophy.
Tan SV, Z'Graggen WJ, Boërio D, Turner C, Hanna MG, Bostock H. Muscle Nerve. 2016 Jan 20. 
 
 
Actinomycin D Specifically Reduces Expanded CUG Repeat RNA in Myotonic Dystrophy Models.
Siboni RB, Nakamori M, Wagner SD, Struck AJ, Coonrod LA, Harriott SA, Cass DM, Tanner MK, Berglund JA. Cell Rep. 2015 Dec 22.
 
Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
Fujita Y, Shinkuma S, Nomura T, Shimizu H. Eur J Dermatol. 2015 Dec 5.
 
 
 
Vital Capacity Impairment due to Neuromuscular Disease and its Correlation with Diaphragmatic Ultrasound: A Preliminary Study.
Carrié C, Bonnardel E, Vally R, Revel P, Marthan R, Biais M. Ultrasound Med Biol. 2015 Nov 24.
 
Undiagnosed myotonic dystrophy type 1 in a patient with synchronous thymoma and thyroid cancer.
Gómez Hernández MT, Martín Posadas MT, García Sánchez MD. Arch Bronconeumol. 2015 Nov 23. 
 
RNA FISH for detecting expanded repeats in human diseases.
Urbanek MO, Krzyzosiak WJ. Methods. 2015 Nov 23. 
 
Atrial electromechanical delay in myotonic dystrophy type 1 patients.
Russo V, Di Meo F, Rago A, Nigro G. Eur Rev Med Pharmacol Sci. 2015 Nov 19. 
 
Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).
Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert JE, Luebbe E, Martens W, McDermott MP, Quinn C, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT 3rd. Neurology. 2015 Nov 18.
 
Percutaneous nephrolithotomy in prone position in patients with spinal deformities.
Izol V, Aridogan IA, Borekoglu A, Gokalp F, Hatipoglu Z, Bayazit Y, Zeren S. Int J Clin Exp Med. 2015 Nov 15.
 
Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions.
Ho G, Cardamone M, Farrar M. World J Clin Pediatr. 2015 Nov 8. 
 
Choline Kinase Beta-Related Muscular Dystrophy, Appearance of Muscle Involvement on Magnetic Resonance Imaging.
De Goede C, Oh T, Joseph J, Muntoni F, Sewry C, Phadke R. Pediatr Neurol. 2015 Nov 5
 
Clinical, pathological and genetic characteristics of a pedigree with myotonic dystrophy type 1.
Liu Q, Zheng YF, Zhu YP, Ling SQ, Li WR. Exp Ther Med. 2015 Nov 10(5):1931-1936. Epub 2015 Sep 9.
 
Rypniewski W, Banaszak K, Kuliński T, Kiliszek A. RNA. 2015 Nov 5. 
 
Schara U. Dev Med Child Neurol. 2015 Nov 4. 
 
Laustriat D, Gide J, Barrault L, Chautard E, Benoit C, Auboeuf D, Boland A, Battail C, Artiguenave F, Deleuze JF, Bénit P, Rustin P, Franc S, Charpentier G, Furling D, Bassez G, Nissan X, Martinat C, Peschanski M, Baghdoyan S. Mol Ther Nucleic Acids. 2015 Nov 3.
 
Sudden cardiac death in neuromuscular disorders.
Finsterer J, Stöllberger C, Maeztu C. Int J Cardiol. 2015 Oct 28.
 
Cocco L, Manzoli L, Faenza I, Ramazzotti G, Yang YR, McCubrey JA, Suh PG, Follo MY. Adv Biol Regul. 2015 Oct 26. 
 
Reconstructing the Rasch-Built Myotonic Dystrophy Type 1 Activity and Participation Scale.
Herman MC, Hoeijmakers JG, Faber CG, Merkies IS. PLoS One. 2015 Oct 20. 
 
Tibialis anterior muscle needle biopsy and sensitive biomolecular methods: a useful tool in myotonic dystrophy type 1.
Iachettini S, Valaperta R, Marchesi A, Perfetti A, Cuomo G, Fossati B, Vaienti L, Costa E, Meola G, Cardani R. Eur J Histochem. 2015 Oct 26.
Case Records of the Massachusetts General Hospital. Case 30-2015: A 50-Year-Old Man with Cardiogenic Shock.
Wheeler TM, Baker JN, Chad DA, Zilinski JL, Verzosa S, Mordes DA. N Engl J Med. 2015 Sep 24. 
 
Guo P, Lam SL. FEBS Lett. 2015 Sep 16. 
 
Brent V, Disney MD. Neuron. 2015 Jul 1. 
 
 
Cooperation Meets Competition in MicroRNA-Mediated DMPK Transcript Regulation.
Koscianska E, Krzyzosiak WJ, et. al. Nucleic Acids Res. 2015 Aug 24. 
 
Prevalence and Correlates of Apathy in Myotonic Dystrophy Type 1.
Gallais B, Laberge L, et. al. BMC Neurol. 2015 Aug 22.
 
Workshop Report: Consensus on Biomarkers of Cerebral Involvmenet in Myotonic Dystrophy.
Bosco G, Meola G, et. al. Neuromuscular Disord. 2015 Aug. 4.
 
 
 
 
 
Congenital Myotonic Dystrophy Type 1 in a Very Premature Neonate: Ethical Concerns.
Van Den Hende K, Cambonie G, et. al. Arch Pediatr. 2015 Aug 25.
 
Finsterer J, Rudnik-Schöneborn S. Fortschr Neurol Psychiatr. 2015 Jan. 

Partners

© Myotonic Dystrophy Foundation. All rights reserved.